<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JPP</journal-id>
<journal-id journal-id-type="hwp">spjpp</journal-id>
<journal-title>Journal of Pharmacy Practice</journal-title>
<issn pub-type="ppub">0897-1900</issn>
<issn pub-type="epub">1531-1937</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0897190011431635</article-id>
<article-id pub-id-type="publisher-id">10.1177_0897190011431635</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The Pharmacotherapy Implications of Ventricular Assist Device in the Patient With End-Stage Heart Failure</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ruden</surname>
<given-names>Serena A. S. Von</given-names>
</name>
<degrees>PharmD, RN, BSN</degrees>
<xref ref-type="aff" rid="aff1-0897190011431635">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Murray</surname>
<given-names>Margaret A.</given-names>
</name>
<degrees>RN, MSN</degrees>
<xref ref-type="aff" rid="aff2-0897190011431635">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Grice</surname>
<given-names>Jennifer L.</given-names>
</name>
<degrees>PharmD, BCPS</degrees>
<xref ref-type="aff" rid="aff3-0897190011431635">3</xref>
<xref ref-type="aff" rid="aff4-0897190011431635">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Proebstle</surname>
<given-names>Amy K.</given-names>
</name>
<degrees>RN, MSN</degrees>
<xref ref-type="aff" rid="aff6-0897190011431635">6</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Kopacek</surname>
<given-names>Karen J.</given-names>
</name>
<degrees>RPh</degrees>
<xref ref-type="aff" rid="aff5-0897190011431635">5</xref>
<xref ref-type="corresp" rid="corresp1-0897190011431635"/>
</contrib>
</contrib-group>
<aff id="aff1-0897190011431635">
<label>1</label>Franciscan Health System, St. Joseph Hospital, 1717 South J Street Tacoma, WA, USA</aff>
<aff id="aff2-0897190011431635">
<label>2</label>Heart, Vascular and Thoracic Department, University of Wisconsin Hospital and Clinics, Madison, WI, USA</aff>
<aff id="aff3-0897190011431635">
<label>3</label>Center for Clinical Knowledge Management, University of Wisconsin Health, Madison, WI, USA</aff>
<aff id="aff4-0897190011431635">
<label>4</label>University of Wisconsin–Madison, School of Pharmacy, Madison, WI, USA</aff>
<aff id="aff5-0897190011431635">
<label>5</label>Pharmacy Practice Division, University of Wisconsin-Madison School of Pharmacy, Madison, WI, USA</aff>
<aff id="aff6-0897190011431635">
<label>6</label>Internal Medicine Department, University of Wisconsin Hospital and Clinics, Madison, WI, USA</aff>
<author-notes>
<corresp id="corresp1-0897190011431635">Karen J. Kopacek, School of Pharmacy, University of Wisconsin–Madison, 1017 Rennebohm Hall, 777 Highland Avenue Madison, WI 53705, USA Email: <email>kjkopacek@pharmacy.wisc.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2012</year>
</pub-date>
<volume>25</volume>
<issue>2</issue>
<fpage>232</fpage>
<lpage>249</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Advances in mechanical circulatory support, such as the use of ventricular assist devices (VADs), have become a means for prolonging survival in end-stage heart failure (HF). VADs decrease the symptoms of HF and improve quality of life by replacing some of the work of a failing heart. They unload the ventricle to provide improved cardiac output and end-organ perfusion, resulting in improvement in cardiorenal syndromes and New York Heart Association functional class rating. VADs are currently used as a bridge to heart transplantation, a bridge to recovery of cardiac function, or as destination therapy. Complications of VAD include bleeding, infections, arrhythmias, multiple organ failure, right ventricular failure, and neurological dysfunction. Patients with VAD have unique pharmacotherapeutic requirements in terms of anticoagulation, appropriate antibiotic selection, and continuation of HF medications. Pharmacists in acute care and community settings are well prepared to care for the patient with VAD. These patients require thorough counseling and follow-up with regard to prevention and treatment of infections, appropriate levels of anticoagulation, and maintenance of fluid balance. A basic understanding of this unique therapy can assist pharmacists in attending to the needs of patients with VAD.</p>
</abstract>
<kwd-group>
<kwd>ventricular assist device</kwd>
<kwd>VAD</kwd>
<kwd>pharmacists</kwd>
<kwd>heart failure</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0897190011431635">
<title>Introduction</title>
<p>Heart failure (HF) is growing in both incidence and prevalence in the United States. A recent report from the American Heart Association estimates that approximately 5.7 million Americans are living with a diagnosis of HF, and an additional 670 000 new diagnoses are made each year.<sup>
<xref ref-type="bibr" rid="bibr1-0897190011431635">1</xref>
</sup> After the age of 65 years, the incidence of HF approaches 10 per 1000 population. The lifetime risk of developing HF is 1 in 5 for both men and women after the age of 40 years. Mortality rates also remain high; the 1-year mortality rate is 20% and &lt;15% of those patients diagnosed with HF survive more than 8 to 12 years. In 2007, there were 56 565 deaths reported as a direct result of HF and 277 193 deaths in which HF was a contributing factor. </p>
<p>The mortality rate for HF continues to increase despite optimization of evidence-based pharmacotherapeutic guidelines.<sup>
<xref ref-type="bibr" rid="bibr2-0897190011431635">2</xref>,<xref ref-type="bibr" rid="bibr3-0897190011431635">3</xref>
</sup> The American Heart Association, American College of Cardiology, and Heart Failure Society of America recommend combination drug therapy that includes angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers, diuretics, aldosterone antagonists, digoxin, and hydralazine in combination with nitrates when indicated. Nonpharmacologic options include placement of implantable cardiodefibrillators (ICDs) and biventricular pacemakers for cardiac resynchronization therapy. Heart transplantation, chronic intravenous inotropes, experimental surgery, and mechanical circulatory support are considered for patients' refractory to other forms of treatment. </p>
<p>Heart transplantation is the preferred therapy for end-stage HF.<sup>
<xref ref-type="bibr" rid="bibr4-0897190011431635">4</xref>
</sup> However, there is currently an imbalance between the supply of and demand for organs available for transplant. More than 3100 patients are on the waiting list for heart transplantation and almost 50% have been waiting for longer than 1 year.<sup>
<xref ref-type="bibr" rid="bibr5-0897190011431635">5</xref>
</sup> In the last decade, over 4000 patients died while waiting for a heart transplant.<sup>
<xref ref-type="bibr" rid="bibr6-0897190011431635">6</xref>
</sup> Additionally, some patients with refractory HF may be ineligible for transplantation due to comorbidities or age. Therefore, advances in mechanical circulatory support, such as ventricular assist devices (VADs), have become a means for prolonging survival in end-stage HF.<sup>
<xref ref-type="bibr" rid="bibr7-0897190011431635">7</xref>,<xref ref-type="bibr" rid="bibr8-0897190011431635">8</xref>
</sup>
</p>
<p>VADs decrease HF symptoms and improve quality of life (QOL) by replacing some of the work of the failing heart. By functioning as a pump, VADs are able to unload the ventricle to improve cardiac output and end-organ perfusion. The left-sided VAD (LVAD) may significantly reverse HF in some patient populations to the extent that mechanical support and heart transplantation are no longer necessary.<sup>
<xref ref-type="bibr" rid="bibr9-0897190011431635">9</xref>
</sup> Many patients who receive VAD therapy return home after implantation and are managed as outpatients. Thus, pharmacists in acute care and community settings should have a general knowledge of these devices to assist patients and caregivers. This review will discuss various types of VADs, their indications for use, the potential benefits and complications associated with therapy, and highlight required pharmacotherapy with implications for the practicing pharmacist. </p>
</sec>
<sec id="section2-0897190011431635">
<title>Background</title>
<sec id="section3-0897190011431635">
<title>History</title>
<p>Mechanical circulatory support includes implanted and percutaneous VADs and intra-aortic balloon pumps (IABPs). Early VADs were developed in the 1960s for use in patients with cardiogenic shock and those unable to wean from cardiopulmonary bypass machine after cardiac surgery.<sup>
<xref ref-type="bibr" rid="bibr10-0897190011431635">10</xref>
</sup> These devices were large extracorporeal machines that required the patient to remain hospitalized on bed rest and resulted in significant complications primarily due to bleeding and infection. In the last two decades, multiple devices have been introduced and approved for use (<xref ref-type="fig" rid="fig1-0897190011431635">Figure 1</xref>). Newer extracorporeal implanted devices displace less blood and are better tolerated by patients than early VADs. Many VADs are now small enough to be implanted pre-peritoneal for either short- or long-term therapy (<xref ref-type="table" rid="table1-0897190011431635">Table 1</xref>). Percutaneous mechanical support systems are used to provide temporary circulatory support after cardiac surgery or coronary intervention but will not be discussed in significant detail in this article.</p>
<fig id="fig1-0897190011431635" position="float">
<label>Figure 1.</label>
<caption>
<p>Chronology of recent ventricular assist devices.<sup>
<xref ref-type="bibr" rid="bibr11-0897190011431635">11</xref>,<xref ref-type="bibr" rid="bibr12-0897190011431635">12</xref>
</sup>
</p>
</caption>
<graphic alternate-form-of="fig1-0897190011431635" xlink:href="10.1177_0897190011431635-fig1.tif"/>
</fig>
<table-wrap id="table1-0897190011431635" position="float">
<label>Table 1.</label>
<caption>
<p>Mechanical Circulatory Support Devices Classified by Type</p>
</caption>
<graphic alternate-form-of="table1-0897190011431635" xlink:href="10.1177_0897190011431635-table1.tif"/>
<table>
<thead>
<tr>
<th>Temporary Implantable Ventricular Assist Device</th>
<th>Permanent Implantable Ventricular Assist Device</th>
<th>Percutaneous Mechanical Support Device</th>
</tr>
</thead>
<tbody>
<tr>
<td>AB 5000<sup>
<xref ref-type="table-fn" rid="table-fn2-0897190011431635">a</xref>
</sup> (formerly known as BVS 5000)</td>
<td>HeartMate XVE<sup>
<xref ref-type="table-fn" rid="table-fn3-0897190011431635">b</xref>
</sup>
</td>
<td>TandemHeart<sup>
<xref ref-type="table-fn" rid="table-fn4-0897190011431635">c</xref>
</sup>
</td>
</tr>
<tr>
<td>CentriMag<sup>
<xref ref-type="table-fn" rid="table-fn5-0897190011431635">d</xref>
</sup>
</td>
<td>HeartMate II<sup>
<xref ref-type="table-fn" rid="table-fn3-0897190011431635">b</xref>
</sup>
</td>
<td>Impella<sup>
<xref ref-type="table-fn" rid="table-fn2-0897190011431635">a</xref>,<xref ref-type="table-fn" rid="table-fn6-0897190011431635">e</xref>
</sup>
</td>
</tr>
<tr>
<td>
</td>
<td>Heartware HVAD<sup>
<xref ref-type="table-fn" rid="table-fn6-0897190011431635">e</xref>,<xref ref-type="table-fn" rid="table-fn7-0897190011431635">f</xref>
</sup>
</td>
<td>
</td>
</tr>
<tr>
<td>
</td>
<td>DuraHeart<sup>
<xref ref-type="table-fn" rid="table-fn6-0897190011431635">e</xref>,<xref ref-type="table-fn" rid="table-fn8-0897190011431635">g</xref>
</sup>
</td>
<td>
</td>
</tr>
<tr>
<td>
</td>
<td>Thoratec PVAD/IVAD<sup>
<xref ref-type="table-fn" rid="table-fn3-0897190011431635">b</xref>
</sup>
</td>
<td>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0897190011431635">
<p>Abbreviations: FDA, US Food and Drug Administration PVAD, paracorporeal ventricular assist device; IVAD, implantable ventricular assist device.</p>
</fn>
<fn id="table-fn2-0897190011431635">
<p>
<sup>a</sup> Abiomed, Danvers, Massachusetts.</p>
</fn>
<fn id="table-fn3-0897190011431635">
<p>
<sup>b</sup> Thoratec Corporation, Pleasanton, California.</p>
</fn>
<fn id="table-fn4-0897190011431635">
<p>
<sup>c</sup> CardiacAssist Inc., Pittsburgh, Pennsylvania.</p>
</fn>
<fn id="table-fn5-0897190011431635">
<p>
<sup>d</sup> Levitronix, Zurich, Switzerland.</p>
</fn>
<fn id="table-fn6-0897190011431635">
<p>
<sup>e</sup> Investigational device awaiting FDA approval.</p>
</fn>
<fn id="table-fn7-0897190011431635">
<p>
<sup>f</sup> Heartware International Inc, Framingham, Massachusetts.</p>
</fn>
<fn id="table-fn8-0897190011431635">
<p>
<sup>g</sup> Terumo Heart, Inc, Ann Arbor, Michigan.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section4-0897190011431635">
<title>Components of a VAD</title>
<p>Most VADs displace blood from the apex of the ventricle via an inflow cannula into a mechanical pump. The pump pushes blood back through an outflow cannula into the ascending aorta or main pulmonary artery, depending on whether the device is supporting the left (LV) or right ventricle (RV), respectively. A few devices displace blood from the atrium instead of the ventricle. The overall effect is to provide support or assistance to the failing ventricle in order to maintain cardiac output. VADs can be used to support the left ventricle (LVAD) or right ventricle (RVAD) in isolation, or both ventricles (bilateral or BiVAD). According to the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS), LVADs are the most commonly implanted devices, followed by BiVADs.<sup>
<xref ref-type="bibr" rid="bibr13-0897190011431635">13</xref>
</sup> The pump can be implanted internally or externally, depending on the expected length of therapy, device type, and patient situation.<sup>
<xref ref-type="bibr" rid="bibr14-0897190011431635">14</xref>
</sup> For an implanted VAD, the pumping component is placed in the abdomen or thorax and is powered by a driveline that exits the skin, attaching to a power supply and an electronic or pneumatic controller (<xref ref-type="fig" rid="fig2-0897190011431635">Figures 2</xref> and <xref ref-type="fig" rid="fig3-0897190011431635">3</xref>). For a temporary implantable VAD, the pump, power supply, and controller are all external to the patient, with a driveline site exiting the chest (<xref ref-type="fig" rid="fig4-0897190011431635">Figure 4</xref>). To date, there is no approved VAD system that is completely implanted. </p>
<fig id="fig2-0897190011431635" position="float">
<label>Figure 2.</label>
<caption>
<p>HeartMate XVE VAD (Thoratec Corporation, Pleasanton, California).<sup>
<xref ref-type="bibr" rid="bibr91-0897190011431635">91</xref>
</sup> Reprinted with permission from Thoratec Corporation. VAD indicates ventricular assist device.</p>
</caption>
<graphic alternate-form-of="fig2-0897190011431635" xlink:href="10.1177_0897190011431635-fig2.tif"/>
</fig>
<fig id="fig3-0897190011431635" position="float">
<label>Figure 3.</label>
<caption>
<p>HeartMate II VAD (Thoratec Corporation, Pleasanton, California).<sup>
<xref ref-type="bibr" rid="bibr92-0897190011431635">92</xref>
</sup> Reprinted with permission from Thoratec Corporation. VAD indiates indicates device.</p>
</caption>
<graphic alternate-form-of="fig3-0897190011431635" xlink:href="10.1177_0897190011431635-fig3.tif"/>
</fig>
<fig id="fig4-0897190011431635" position="float">
<label>Figure 4.</label>
<caption>
<p>CentriMag (Levitronix, Zurich, Switzerland) temporary implantable VAD.<sup>
<xref ref-type="bibr" rid="bibr18-0897190011431635">18</xref>
</sup> Reprinted with permission from Levitronix. VAD indicates ventricular assist device.</p>
</caption>
<graphic alternate-form-of="fig4-0897190011431635" xlink:href="10.1177_0897190011431635-fig4.tif"/>
</fig>
</sec>
<sec id="section5-0897190011431635">
<title>Classifications of VADs</title>
<p>VADs are described by anticipated length of therapy (temporary or permanent) and location (implanted or percutaneous), and classified by pump design (type and generation). </p>
<p>There are 3 main pump designs or generations for VADs. One design propels blood in a pulsatile manner while others continuously propel blood through the device (<xref ref-type="table" rid="table2-0897190011431635">Table 2</xref>). Blood exits the native left ventricle through the inflow cannula into the pumping chamber or sac. Pulsatile pumps (or first-generation VADs) use electrically or pneumatically powered plates to contract a polyurethane diaphragm and eject blood (<xref ref-type="fig" rid="fig5-0897190011431635">Figure 5</xref>).<sup>
<xref ref-type="bibr" rid="bibr11-0897190011431635">11</xref>
</sup> The resulting stroke volume produces a pulse and blood pressure (BP) mimicking the action of the native heart. First-generation VADs are bulky, noisy, and may fail over time due to prolonged wearing of the moving mechanical parts.<sup>
<xref ref-type="bibr" rid="bibr10-0897190011431635">10</xref>
</sup> These VADs contain prosthetic valves to ensure unidirectional blood flow which may also degrade with time. </p>
<fig id="fig5-0897190011431635" position="float">
<label>Figure 5.</label>
<caption>
<p>Cross section of the pulsatile pump from a HeartMate XVE VAD (Thoratec Corporation, Pleasanton, California).<sup>
<xref ref-type="bibr" rid="bibr91-0897190011431635">91</xref>
</sup> Reprinted with permission from Thoratec Corporation.</p>
</caption>
<graphic alternate-form-of="fig4-0897190011431635" xlink:href="10.1177_0897190011431635-fig5.tif"/>
</fig>
<table-wrap id="table2-0897190011431635" position="float">
<label>Table 2.</label>
<caption>
<p>Mechanical Circulatory Support Devices Classified by Generation<sup>
<xref ref-type="bibr" rid="bibr10-0897190011431635">10</xref>,<xref ref-type="bibr" rid="bibr13-0897190011431635">13</xref>,<xref ref-type="bibr" rid="bibr15-0897190011431635">15</xref>
</sup>
</p>
</caption>
<graphic alternate-form-of="table2-0897190011431635" xlink:href="10.1177_0897190011431635-table2.tif"/>
<table>
<thead>
<tr>
<th>First-Generation Ventricular Assist Devices (Pulsatile Pumps)</th>
<th>Second-Generation Ventricular Assist Devices (Continuous Flow Centrifugal or Axial Pumps)</th>
<th>Third-Generation Ventricular Assist Devices (Continuous Flow Magnetic Pumps)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AB 5000<sup>
<xref ref-type="table-fn" rid="table-fn10-0897190011431635">a</xref>
</sup> (formerly known as BVS 5000)</td>
<td>MicroMed DeBakey<sup>
<xref ref-type="table-fn" rid="table-fn11-0897190011431635">b</xref>,<xref ref-type="table-fn" rid="table-fn12-0897190011431635">c</xref>
</sup>
</td>
<td>CentriMag<sup>
<xref ref-type="table-fn" rid="table-fn13-0897190011431635">d</xref>
</sup>
</td>
</tr>
<tr>
<td>HeartMate IP<sup>
<xref ref-type="table-fn" rid="table-fn14-0897190011431635">e</xref>
</sup>
</td>
<td>Jarvik 2000<sup>
<xref ref-type="table-fn" rid="table-fn12-0897190011431635">c</xref>,<xref ref-type="table-fn" rid="table-fn15-0897190011431635">f</xref>
</sup>
</td>
<td>HVAD (Heartware VAD)<sup>
<xref ref-type="table-fn" rid="table-fn12-0897190011431635">c</xref>,<xref ref-type="table-fn" rid="table-fn16-0897190011431635">g</xref>
</sup>
</td>
</tr>
<tr>
<td>Thoratec PVAD/IVAD<sup>
<xref ref-type="table-fn" rid="table-fn14-0897190011431635">e</xref>
</sup>
</td>
<td>Impella<sup>
<xref ref-type="table-fn" rid="table-fn10-0897190011431635">a</xref>,<xref ref-type="table-fn" rid="table-fn12-0897190011431635">c</xref>
</sup>
</td>
<td>DuraHeart<sup>
<xref ref-type="table-fn" rid="table-fn12-0897190011431635">c</xref>,<xref ref-type="table-fn" rid="table-fn17-0897190011431635">h</xref>
</sup>
</td>
</tr>
<tr>
<td>Novacor<sup>
<xref ref-type="table-fn" rid="table-fn18-0897190011431635">i</xref>
</sup>
</td>
<td>TandemHeart<sup>
<xref ref-type="table-fn" rid="table-fn19-0897190011431635">j</xref>
</sup>
</td>
<td>
</td>
</tr>
<tr>
<td>HeartMate VE<sup>
<xref ref-type="table-fn" rid="table-fn14-0897190011431635">e</xref>
</sup>
</td>
<td>HeartMate II<sup>
<xref ref-type="table-fn" rid="table-fn14-0897190011431635">e</xref>
</sup>
</td>
<td>
</td>
</tr>
<tr>
<td>HeartMate XVE<sup>
<xref ref-type="table-fn" rid="table-fn14-0897190011431635">e</xref>
</sup>
</td>
<td>
</td>
<td>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn9-0897190011431635">
<p>Abbreviations: FDA, US Food and Drug Administration PVAD, paracorporeal ventricular assist device; IVAD, implantable ventricular assist device.</p>
</fn>
<fn id="table-fn10-0897190011431635">
<p>
<sup>a</sup> Abiomed, Danvers, Massachusetts.</p>
</fn>
<fn id="table-fn11-0897190011431635">
<p>
<sup>b</sup> Micromed Microvascular Inc., Houston, Texas.</p>
</fn>
<fn id="table-fn12-0897190011431635">
<p>
<sup>c</sup> Investigational device awaiting FDA approval.</p>
</fn>
<fn id="table-fn13-0897190011431635">
<p>
<sup>d</sup> Levitronix, Zurich, Switzerland.</p>
</fn>
<fn id="table-fn14-0897190011431635">
<p>
<sup>e</sup> Thoratec Corporation, Pleasanton, California.</p>
</fn>
<fn id="table-fn15-0897190011431635">
<p>
<sup>f</sup> Jarvik Heart Inc, New York, New York.</p>
</fn>
<fn id="table-fn16-0897190011431635">
<p>
<sup>g</sup> Heartware International Inc, Framingham, Massachusetts.</p>
</fn>
<fn id="table-fn17-0897190011431635">
<p>
<sup>h</sup> Terumo Heart, Inc, Ann Arbor, Michigan.</p>
</fn>
<fn id="table-fn18-0897190011431635">
<p>
<sup>i</sup> World Heart Corporation, Ottawa, Ontario, Canada.</p>
</fn>
<fn id="table-fn19-0897190011431635">
<p>
<sup>j</sup> CardiacAssist Inc, Pittsburgh, Pennsylvania.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Second-generation VADs utilize continuous flow technology via axial or centrifugal mechanisms.<sup>
<xref ref-type="bibr" rid="bibr10-0897190011431635">10</xref>
</sup> Continuous flow pumps push blood in a forward direction using either a rotary propeller or a concentric cones to accelerate blood in a centrifugal manner (<xref ref-type="fig" rid="fig6-0897190011431635">Figure 6</xref>).<sup>
<xref ref-type="bibr" rid="bibr10-0897190011431635">10</xref>,<xref ref-type="bibr" rid="bibr13-0897190011431635">13</xref>
</sup> Unlike pulsatile pumps, second-generation VADs do not require valves or chambers due to constant blood flow. Therefore, patients with a continuous flow VAD generally do not have a palpable pulse or a BP that can be measured with sphygmomanometer. In this patient population, noninvasive BP is measured using a handheld Doppler device to determine mean arterial pressure. With only one moving part, second-generation VADs are smaller in size, quieter, and subject to less wear and mechanical failure.<sup>
<xref ref-type="bibr" rid="bibr10-0897190011431635">10</xref>
</sup> However, studies have not demonstrated a difference between pulsatile and continuous flow VADs in terms of end-organ perfusion or patient outcomes.<sup>
<xref ref-type="bibr" rid="bibr14-0897190011431635">14</xref>
<xref ref-type="bibr" rid="bibr15-0897190011431635"/>–<xref ref-type="bibr" rid="bibr16-0897190011431635">16</xref>
</sup> </p>
<fig id="fig6-0897190011431635" position="float">
<label>Figure 6.</label>
<caption>
<p>Cross section of the continuous flow rotary pump from a HeartMate II VAD (Thoratec Corportation, Pleasanton, California).<sup>
<xref ref-type="bibr" rid="bibr92-0897190011431635">92</xref>
</sup> Reprinted with permission from Thoratec Corporation.</p>
</caption>
<graphic alternate-form-of="fig6-0897190011431635" xlink:href="10.1177_0897190011431635-fig6.tif"/>
</fig>
<p>Third-generation VADs are currently under investigation in the United States. These devices are continuous flow pumps powered through magnetic levitation.<sup>
<xref ref-type="bibr" rid="bibr17-0897190011431635">17</xref>
</sup> The Heartware HVAD and DuraHeart are permanent implantable VADs which are smaller in size than previous generations and lack mechanical bearings. The CentriMag is a temporary implantable VAD that also lacks bearings and seals (<xref ref-type="fig" rid="fig7-0897190011431635">Figure 7</xref>).<sup>
<xref ref-type="bibr" rid="bibr18-0897190011431635">18</xref>
</sup> The decreased friction associated with magnetic levitation-driven rotation has implications for fewer complications such as hemolysis and mechanical pump failure.</p>
<fig id="fig7-0897190011431635" position="float">
<label>Figure 7.</label>
<caption>
<p>Cross section of the continuous flow magnetic levitation pump from a CentriMag temporary implantable VAD (Levitronix, Zurich, Switzerland).<sup>
<xref ref-type="bibr" rid="bibr18-0897190011431635">18</xref>
</sup> Reprinted with permission from Levitronix.</p>
</caption>
<graphic alternate-form-of="fig7-0897190011431635" xlink:href="10.1177_0897190011431635-fig7.tif"/>
</fig>
</sec>
<sec id="section6-0897190011431635">
<title>Patient Candidates</title>
<p>There are currently no consensus guidelines to identify eligible patients for VAD implantation.<sup>
<xref ref-type="bibr" rid="bibr19-0897190011431635">19</xref>
</sup> Eligibility criteria are typically VAD center specific; however, institutions tend to utilize similar standards. Potential candidates include patients with end-stage HF or cardiogenic shock refractory to medical treatment, left ventricular ejection fraction (EF) ≤25%, intractable ventricular arrhythmias, or those on continuous intravenous inotropic therapy. Although device specific, a body surface area &gt;1.5 m<sup>2</sup> is generally required for pre-peritoneal or thoracic VAD placement. General contraindications to implantation include failure of a second or third major organ system, metastatic cancer, active infection, or neuropsychological or social issues that would impair a patient's ability to care for himself or herself. </p>
</sec>
<sec id="section7-0897190011431635">
<title>Indications for Use</title>
<p>Mechanical circulatory support devices (VADs and percutaneous mechanical support systems) are US Food and Drug Administration (FDA) approved for one or more indications: bridge to transplant (BTT), bridge to recovery (BTR), and destination therapy ([DT] <xref ref-type="table" rid="table3-0897190011431635">Table 3</xref>). VADs are often used as BTT in eligible patients waiting for heart transplantation. According to the INTERMACS registry, BTT was the indication listed for 80% of VAD implantations.<sup>
<xref ref-type="bibr" rid="bibr20-0897190011431635">20</xref>
</sup> In BTT, the VAD is implanted to prolong a patient's survival while waiting for a suitable heart to become available for transplant. Studies demonstrate that patients bridged with a VAD have similar<sup>
<xref ref-type="bibr" rid="bibr21-0897190011431635">21</xref>,<xref ref-type="bibr" rid="bibr22-0897190011431635">22</xref>
</sup> or improved<sup>
<xref ref-type="bibr" rid="bibr8-0897190011431635">8</xref>
</sup> postcardiac transplant survival as compared to those who did not receive VAD support. Another potential benefit of BTT is decreased patient mortality while waiting for transplantation.</p>
<table-wrap id="table3-0897190011431635" position="float">
<label>Table 3.</label>
<caption>
<p>Indications for Mechanical Circulatory Support Devices<sup>
<xref ref-type="bibr" rid="bibr8-0897190011431635">8</xref>,<xref ref-type="bibr" rid="bibr17-0897190011431635">17</xref>
</sup>
</p>
</caption>
<graphic alternate-form-of="table3-0897190011431635" xlink:href="10.1177_0897190011431635-table3.tif"/>
<table>
<thead>
<tr>
<th>Bridge to Transplant</th>
<th>Bridge to Recovery</th>
<th>Destination Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thoratec PVAD/IVAD<sup>
<xref ref-type="table-fn" rid="table-fn21-0897190011431635">a</xref>
</sup>
</td>
<td>BVS 5000 (now called AB 5000)<sup>
<xref ref-type="table-fn" rid="table-fn22-0897190011431635">b</xref>
</sup>
</td>
<td>HeartMate XVE<sup>
<xref ref-type="table-fn" rid="table-fn21-0897190011431635">a</xref>
</sup>
</td>
</tr>
<tr>
<td>HeartMate XVE<sup>
<xref ref-type="table-fn" rid="table-fn21-0897190011431635">a</xref>
</sup>
</td>
<td>Thoratec PVAD/IVAD<sup>
<xref ref-type="table-fn" rid="table-fn21-0897190011431635">a</xref>
</sup>
</td>
<td>HeartMate II<sup>
<xref ref-type="table-fn" rid="table-fn21-0897190011431635">a</xref>
</sup>
</td>
</tr>
<tr>
<td>HeartMate II<sup>
<xref ref-type="table-fn" rid="table-fn21-0897190011431635">a</xref>
</sup>
</td>
<td>HeartMate XVE<sup>
<xref ref-type="table-fn" rid="table-fn21-0897190011431635">a</xref>
</sup>
</td>
<td>HVAD (Heartware VAD)<sup>
<xref ref-type="table-fn" rid="table-fn23-0897190011431635">c</xref>,<xref ref-type="table-fn" rid="table-fn24-0897190011431635">d</xref>
</sup>
</td>
</tr>
<tr>
<td>HVAD (Heartware VAD)<sup>
<xref ref-type="table-fn" rid="table-fn23-0897190011431635">c</xref>,<xref ref-type="table-fn" rid="table-fn24-0897190011431635">d</xref>
</sup>
</td>
<td>Impella<sup>
<xref ref-type="table-fn" rid="table-fn22-0897190011431635">b</xref>,<xref ref-type="table-fn" rid="table-fn24-0897190011431635">d</xref>
</sup>
</td>
<td>DuraHeart<sup>
<xref ref-type="table-fn" rid="table-fn24-0897190011431635">d</xref>,<xref ref-type="table-fn" rid="table-fn25-0897190011431635">e</xref>
</sup>
</td>
</tr>
<tr>
<td>DuraHeart<sup>
<xref ref-type="table-fn" rid="table-fn24-0897190011431635">d</xref>,<xref ref-type="table-fn" rid="table-fn25-0897190011431635">e</xref>
</sup>
</td>
<td>TandemHeart<sup>
<xref ref-type="table-fn" rid="table-fn26-0897190011431635">f</xref>
</sup>
</td>
<td>
</td>
</tr>
<tr>
<td>
</td>
<td>Centrimag<sup>
<xref ref-type="table-fn" rid="table-fn27-0897190011431635">g</xref>,<xref ref-type="table-fn" rid="table-fn28-0897190011431635">h</xref>
</sup>
</td>
<td>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn20-0897190011431635">
<p>Abbreviations: FDA, US Food and Drug Administration PVAD, paracorporeal ventricular assist device; IVAD, implantable ventricular assist device.</p>
</fn>
<fn id="table-fn21-0897190011431635">
<p>
<sup>a</sup> Thoratec Corporation, Pleasanton, California.</p>
</fn>
<fn id="table-fn22-0897190011431635">
<p>
<sup>b</sup> Abiomed, Danvers, Massachusetts.</p>
</fn>
<fn id="table-fn23-0897190011431635">
<p>
<sup>c</sup> Heartware International Inc, Framingham, Massachusetts.</p>
</fn>
<fn id="table-fn24-0897190011431635">
<p>
<sup>d</sup> Awaiting FDA approval for this indication.</p>
</fn>
<fn id="table-fn25-0897190011431635">
<p>
<sup>e</sup> Terumo Heart, Inc, Ann Arbor, Michigan.</p>
</fn>
<fn id="table-fn26-0897190011431635">
<p>
<sup>f</sup> CardiacAssist Inc, Pittsburgh, Pennsylvania.</p>
</fn>
<fn id="table-fn27-0897190011431635">
<p>
<sup>g</sup> Levitronix, Zurich, Switzerland.</p>
</fn>
<fn id="table-fn28-0897190011431635">
<p>
<sup>h</sup> Approved for right ventricular support up to 30 days and total cardiac support up to 6 hours; other indications under investigation.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Mechanical circulatory support devices were initially used as BTR after cardiac surgery or cardiogenic shock to allow the heart to rest and recover function.<sup>
<xref ref-type="bibr" rid="bibr23-0897190011431635">23</xref>
</sup> VADs and percutaneous mechanical support systems are still used for this indication to support the heart until the device is no longer needed. In this population, long-term survival for patients receiving implanted mechanical circulatory support is statistically equivalent to those receiving heart transplants for an acute cardiac pump failure.<sup>
<xref ref-type="bibr" rid="bibr24-0897190011431635">24</xref>
</sup> While circulatory support can be short term (a few hours), it is generally for a duration ranging from less than 2 weeks and up to 6 months or more. The goal of BTR is explantation of the device once adequate cardiac function is achieved. BTR is the listed indication for 5% of patients registered with INTERMACS.<sup>
<xref ref-type="bibr" rid="bibr20-0897190011431635">20</xref>
</sup> </p>
<p>A subset of BTR is bridge to decision (BTD) or bridge to candidacy, which is an unofficial, non-FDA-approved indication. Mechanical circulatory support is used for BTD when a patient requires stabilization and some degree of recovery before the health care team can decide on the final goal of therapy. The time provided by mechanical circulatory support allows for the patient to undergo evaluation for heart transplant or permanent VAD. Additionally, BTD can provide time for the patient to recover, state his or her wishes, and take part in decision making. In this setting, the goal of BTD is the transition to a more permanent solution such as implantable VAD, heart transplantation, or device explantation.</p>
<p>Patients with end-stage HF who are not candidates for heart transplantation may be candidates for VAD therapy. This VAD only indication (not for percutaneous mechanical support systems) is termed destination therapy (DT) and is generally reserved for patients with New York Heart Association (NYHA) functional class IV disease who are ineligible for heart transplantation and have a life expectancy of &lt;2 years despite optimization of medical therapy.<sup>
<xref ref-type="bibr" rid="bibr25-0897190011431635">25</xref>
</sup> Fifteen percent of the patients registered through INTERMACS received a VAD for this indication.<sup>
<xref ref-type="bibr" rid="bibr20-0897190011431635">20</xref>
</sup> Second-generation devices have lower rates of complications and greater device longevity (5-10 years)<sup>
<xref ref-type="bibr" rid="bibr26-0897190011431635">26</xref>
</sup> and several are currently being studied for a DT indication. The continuous flow rotary HeartMate II was the first device to receive FDA approval for DT.<sup>
<xref ref-type="bibr" rid="bibr27-0897190011431635">27</xref>
</sup> Implantable third-generation devices, such as Heartware HVAD and DuraHeart, are also in clinical trials for DT approval.</p>
</sec>
</sec>
<sec id="section8-0897190011431635">
<title>Outcomes</title>
<sec id="section9-0897190011431635">
<title>Benefits</title>
<p>The Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group was the pivotal trial reporting the ability of LVAD therapy to significantly improve QOL and prolong survival in patients receiving DT.<sup>
<xref ref-type="bibr" rid="bibr7-0897190011431635">7</xref>
</sup> This study was a multicenter trial involving 129 patients with NYHA class IV HF refractory to optimized medical therapy and ineligible for cardiac transplant. The patients were randomized to LVAD with HeartMate XVE or continued optimization of pharmacotherapy and medical treatments. One year survival rates were significantly higher in the LVAD group compared to the medical treatment group (52% vs 25%, respectively; <italic>P</italic> = .002). Implantation of LVAD was associated with a relative risk reduction in death of 48% and an absolute risk reduction of 27% after 1 year. The implication of this result is for every 1000 patients with end-stage HF, LVAD therapy could prevent 270 deaths annually. Subsequent work has shown that survival in the DT setting can be further improved when patients receive a VAD before significant HF complications or end-organ damage has occurred.<sup>
<xref ref-type="bibr" rid="bibr28-0897190011431635">28</xref>
</sup> QOL (<italic>P</italic> = .01), Beck Depression Inventory scores (<italic>P</italic> = .04), and NYHA functional class (<italic>P</italic> &lt; .001) also demonstrated significant improvements after 1 year of LVAD therapy.<sup>
<xref ref-type="bibr" rid="bibr7-0897190011431635">7</xref>
</sup> However, patients in the LVAD group were more than twice as likely to have serious adverse events (rate ratio (RR) 2.35, 95% confidence interval (CI) 1.86-2.95) compared to the medical treatment patients. Patients with a LVAD were more likely to experience nonneurologic bleeding (RR 9.47; 95% CI 2.3-38.9) neurologic dysfunction (RR 4.25; 95% CI 1.31-14.5), peripheral embolic event (RR 2.29; 95% CI 0.48-10.8), and sepsis (RR 2.03; 95% CI 0.99-4.12) versus those receiving medical management. </p>
<p>Multiple studies have also demonstrated improvements in overall QOL after VAD implantation.<sup>
<xref ref-type="bibr" rid="bibr29-0897190011431635">29</xref>
<xref ref-type="bibr" rid="bibr30-0897190011431635"/>
<xref ref-type="bibr" rid="bibr31-0897190011431635"/>–<xref ref-type="bibr" rid="bibr32-0897190011431635">32</xref>
</sup> Grady et al noted high degrees of patient satisfaction and perception of QOL in as little as 1 to 2 weeks post device implantation.<sup>
<xref ref-type="bibr" rid="bibr29-0897190011431635">29</xref>
</sup> These findings were significantly higher than measurements taken immediately preoperatively, showing an improvement in QOL after VAD implantation in patients with end-stage HF (<italic>P</italic> = .02). This was especially true with regard to perception of health status (<italic>P</italic> = .001) and improvement in symptoms of exertional shortness of breath (<italic>P</italic> &lt; .0001) and weakness (<italic>P</italic> = .008). In another study by Grady et al, investigators reported further improvement in reported disability and reduction in stress following hospital discharge in patients who received a VAD as compared to those who remained hospitalized after VAD implantation.<sup>
<xref ref-type="bibr" rid="bibr30-0897190011431635">30</xref>
</sup> Dew et al also noted an increase in measured QOL indicators for those VAD patients allowed to be managed as outpatients.<sup>
<xref ref-type="bibr" rid="bibr31-0897190011431635">31</xref>
</sup> In the DT population who received LVAD, the QOL scores remained stable from 1 month to 1 year postimplantation.<sup>
<xref ref-type="bibr" rid="bibr32-0897190011431635">32</xref>
</sup> </p>
<p>A study conducted by Frazier et al demonstrated improvements in NYHA functional class during HeartMate XVE therapy in a BTT population.<sup>
<xref ref-type="bibr" rid="bibr8-0897190011431635">8</xref>
</sup> This multicenter trial involved LVAD implantation into 280 cardiac transplant candidates refractory to medical treatment as compared to an historic control group of 48 patients not receiving a LVAD. Of the 160 patients with a LVAD who became eligible for hospital discharge, 100% were discharged at NYHA class I or II compared with 96% (153 patients) beginning the study at NYHA class IV. Despite significant complication rates, 71% of patients receiving LVAD therapy survived until cardiac transplant compared to 33% of those in the control group (<italic>P</italic> &lt; .001). The most commonly reported device-related adverse events were infection (40%), bleeding (11%), thrombotic events (6%), and neurologic dysfunction (5%).</p>
<p>In the same study, Frazier et al also reported a statistically significant improvement in end-organ perfusion after implantation.<sup>
<xref ref-type="bibr" rid="bibr8-0897190011431635">8</xref>
</sup> Median total bilirubin level decreased from 1.2 to 0.7 mg/dL (<italic>P</italic> = .0001) and median creatinine level decreased from 1.5 (<italic>P</italic> = .0001) to 1.1 mg/dL. Improvements in renal and hepatic function due to increased perfusion have been confirmed in clinical trials using other VAD for DT<sup>
<xref ref-type="bibr" rid="bibr33-0897190011431635">33</xref>
</sup> and BTT indications.<sup>
<xref ref-type="bibr" rid="bibr34-0897190011431635">34</xref>,<xref ref-type="bibr" rid="bibr35-0897190011431635">35</xref>
</sup> Improvement in end-organ function can lead to an increased overall survival rate.<sup>
<xref ref-type="bibr" rid="bibr36-0897190011431635">36</xref>
</sup>
</p>
<p>The ability of the VAD to unload the failing ventricle can lead to improvements in hemodynamic measurements, such as increased EF and reductions in peak oxygen consumption and pulmonary capillary wedge pressures, that correlates with functional improvement.<sup>
<xref ref-type="bibr" rid="bibr33-0897190011431635">33</xref>
</sup> Patients who received a LVAD in the REMATCH study had improved exercise tolerance as evidenced by fewer reported limitations associated with climbing one (<italic>P</italic> = .006) or more flights of stairs (<italic>P</italic> = .008) and walking one block at a time (<italic>P</italic> = .004).<sup>
<xref ref-type="bibr" rid="bibr7-0897190011431635">7</xref>
</sup> </p>
<p>Some patients receiving VAD therapy have demonstrated such significant improvement in HF symptoms to allow for device explantation.<sup>
<xref ref-type="bibr" rid="bibr8-0897190011431635">8</xref>,<xref ref-type="bibr" rid="bibr9-0897190011431635">9</xref>
</sup> Birks et al conducted a prospective study in 20 patients implanted with a HeartMate XVE LVAD for nonischemic cardiomyopathy.<sup>
<xref ref-type="bibr" rid="bibr9-0897190011431635">9</xref>
</sup> Patients were also treated with standard HF therapies after implantation to enhance reverse ventricular remodeling. Once maximum decreases in left ventricular end-diastolic diameter were reached, patients were initiated on the beta-agonist, clenbuterol. Of the 15 patients able to complete full titration of clenbuterol, 11 (73%) met criteria for VAD explantation with mean improvement in left ventricular EF from 12% ± 6% to 64% ± 8% (<italic>P</italic> = .001). A retrospective review of 35 patients with HF predicts that patients with recent nonischemic cardiomyopathy, EF &gt;45%, and those on optimized medical therapy are most likely to show recovery and successful weaning from VAD support.<sup>
<xref ref-type="bibr" rid="bibr37-0897190011431635">37</xref>
</sup>
</p>
<p>Post-marketing data analyzing outcomes in patients with VADs for BTT indication was recently published.<sup>
<xref ref-type="bibr" rid="bibr38-0897190011431635">38</xref>
</sup> This multicenter prospective study followed 338 patients enrolled in the INTERMACS registry receiving either the HeartMate II (n = 169) or other comparison VAD (n = 169, HeartMate XVE or Thoratec IVAD). At 6 months, survival to transplant, recovery of cardiac function, or continuation of VAD therapy was 90% in the HeartMate II group versus 80% in the comparison group (<italic>P</italic> = .018). Twelve-month survival for those patients not receiving a heart transplant or able to undergo explantation was 85% and 70%, respectively. This study also confirmed that QOL improves after VAD implantation despite adverse effects. Patients in both study groups reported improved QOL at 3 months of therapy that was sustained through 1 year compared to baseline (<italic>P</italic> &lt; .0001). Adverse events such as bleeding, infection, end-organ failure, cardiac arrhythmias, hemolysis, and stroke were noted in both groups.</p>
</sec>
<sec id="section10-0897190011431635">
<title>Complications</title>
<p>A high incidence of adverse events occur during VAD therapy; approximately 80% to 90% of patients experience at least one clinically significant adverse event.<sup>
<xref ref-type="bibr" rid="bibr38-0897190011431635">38</xref> </sup>The most commonly noted adverse events include infection, bleeding, arrhythmias, and reoperations, with most occurring within 1 to 2 months after surgery.<sup>
<xref ref-type="bibr" rid="bibr38-0897190011431635">38</xref>
<xref ref-type="bibr" rid="bibr39-0897190011431635"/>
<xref ref-type="bibr" rid="bibr40-0897190011431635"/>
<xref ref-type="bibr" rid="bibr41-0897190011431635"/>–<xref ref-type="bibr" rid="bibr42-0897190011431635">42</xref> </sup>Immediate postoperative complications for VAD implantation are similar to those noted after open heart surgery as both require a median sternotomy incision and placement on cardiopulmonary bypass machine. Complications associated with both surgical procedures include bleeding, infection from surgical and nonsurgical sources, arrhythmias, renal failure, and neurological dysfunction.<sup>
<xref ref-type="bibr" rid="bibr40-0897190011431635">40</xref>
<xref ref-type="bibr" rid="bibr41-0897190011431635"/>–<xref ref-type="bibr" rid="bibr42-0897190011431635">42</xref>
</sup> Other possible complications associated with VAD surgery include stroke, VAD malfunction, RV failure, and liver failure.<sup>
<xref ref-type="bibr" rid="bibr43-0897190011431635">43</xref>
<xref ref-type="bibr" rid="bibr44-0897190011431635"/>
<xref ref-type="bibr" rid="bibr45-0897190011431635"/>–<xref ref-type="bibr" rid="bibr46-0897190011431635">46</xref>
</sup> These complications may occur early in the postoperative course<sup>
<xref ref-type="bibr" rid="bibr47-0897190011431635">47</xref>
</sup> or may not occur until a patient has discharged from the hospital. Such complications can negatively affect a patient's survival and increase his or her complexity of care.</p>
<sec id="section11-0897190011431635">
<title>Infection</title>
<p>Infection can occur in any postoperative surgical patient or with any implanted device.<sup>
<xref ref-type="bibr" rid="bibr48-0897190011431635">48</xref>
<xref ref-type="bibr" rid="bibr49-0897190011431635"/>–<xref ref-type="bibr" rid="bibr50-0897190011431635">50</xref>
</sup> An analysis of recent data from INTERMACS reported infection rates during the first year after VAD implantation of 42% to 46%.<sup>
<xref ref-type="bibr" rid="bibr39-0897190011431635">39</xref>
</sup> To minimize the risk of postoperative complications due to infection, all VAD patients should be cultured for potential sources of existing infections preoperatively and receive prophylactic antimicrobials in the pre- and immediate postoperative phases. Generally, prophylaxis is broad spectrum<sup>
<xref ref-type="bibr" rid="bibr7-0897190011431635">7</xref>
</sup> although the specific medications used differ by institution. VAD implantation should be cancelled in patients with positive preoperative cultures or evidence of infection.<sup>
<xref ref-type="bibr" rid="bibr39-0897190011431635">39</xref>
</sup> Host-related factors can increase the patient's risk for postoperative infections and include immune status, malnutrition, and diabetes mellitus.<sup>
<xref ref-type="bibr" rid="bibr51-0897190011431635">51</xref>
</sup> It has also been noted that obesity may also increase the incidence of infection in patients with a VAD.<sup>
<xref ref-type="bibr" rid="bibr52-0897190011431635">52</xref> </sup>
</p>
<p>Infections in patients with a VAD can be divided into 2 general categories, device or nondevice related. In general, all infections must be treated aggressively to avoid organism adherence to the VAD which may result in device-related endocarditis. Terminology differs for the various sites of device-related infections. A driveline infection is purulent drainage with or without cellulitis at the exit site.<sup>
<xref ref-type="bibr" rid="bibr53-0897190011431635">53</xref>
</sup> Pocket infections consist of purulent fluid within the VAD pocket or a microbe cultured from the pump pocket at VAD explant. Mediastinitis is characterized by purulent fluid in the mediastinum or microbe cultured from the mediastinum at VAD explant. Finally, pump endocarditis is defined as the colonization of blood contacting the device surfaces.<sup>
<xref ref-type="bibr" rid="bibr54-0897190011431635">54</xref>
</sup> Pump endocarditis is the most severe infection, requiring long-term antibiotic therapy until the VAD is replaced or heart transplantation with VAD explant occurs.<sup>
<xref ref-type="bibr" rid="bibr55-0897190011431635">55</xref>
</sup> An infected VAD is not a contraindication to transplant; transplantation may provide a definitive cure to pump endocarditis despite the required postoperative immunosuppressant therapies.<sup>
<xref ref-type="bibr" rid="bibr56-0897190011431635">56</xref>
</sup>
</p>
<p>The 2 most common types of device-related infections are associated with the VAD driveline and pump.<sup>
<xref ref-type="bibr" rid="bibr7-0897190011431635">7</xref>,<xref ref-type="bibr" rid="bibr55-0897190011431635">55</xref>,<xref ref-type="bibr" rid="bibr57-0897190011431635">57</xref>
</sup> Driveline infections can be more common in first-generation devices due to the large, rigid driveline. In comparison, second- and third-generation devices have smaller, more flexible drivelines. However, recent data from the INTERMACS registry analysis reported similar driveline infection rates between patients who received a HeartMate II VAD and those with a HeartMate XVE or Thoratec IVAD (17.8% vs 16%, respectively; <italic>P</italic> = .1419).<sup>
<xref ref-type="bibr" rid="bibr39-0897190011431635">39</xref>
</sup> To minimize the risk for driveline infections, patients and caregivers are taught how to perform daily sterile dressing changes and must demonstrate proper dressing process prior to hospital discharge. If a driveline infection occurs, the goal of therapy is to keep the infection confined to the skin exit site, preventing its ascending movement toward the pump. Pump infections may lead to bacteremia and sepsis. In the situation of bacteremia, the VAD is always presumed to be a source of infection and may require long-term antibiotic treatment. The rate of VAD-associated sepsis reported in the recent INTERMACS registry ranged from 18.9% to 21.3%.<sup>
<xref ref-type="bibr" rid="bibr39-0897190011431635">39</xref>
</sup>
</p>
<p>Pump infections and driveline infections near the pump may result in painful effusions. In patients with pump infection at the implant site, fluid can build up around the VAD and push on surrounding tissues or nerves causing pain. Treatment includes either drainage in combination with antibiotics, pump exchange, or antibiotics alone.</p>
<p>Device-related infections do not prevent heart transplantation. Patients with a VAD for BTT indication have been transplanted successfully despite pump or driveline infections. Early research reported that infections susceptible to antibiotics did not adversely affect mortality rates post-transplantation.<sup>
<xref ref-type="bibr" rid="bibr58-0897190011431635">58</xref>
</sup> However, more recent information argues that these infections do negatively affect survival, particularly in patients with VAD endocarditis (<italic>P</italic> = .017) and increase the duration of mechanical support compared to patients without VAD infections (median 125 days vs 25 days, respectively; <italic>P</italic> = .003).<sup>
<xref ref-type="bibr" rid="bibr53-0897190011431635">53</xref>
</sup> </p>
<p>Nondevice-related infections such as pneumonia or urinary tract infection also require aggressive treatment and frequent patient monitoring for repeat infections. If a patient develops repeated infections from the same source, he or she should be referred to an Infectious Disease specialist to assist with control or management.</p>
</sec>
<sec id="section12-0897190011431635">
<title>Bleeding</title>
<p>Studies have consistently shown that bleeding is the most common adverse event associated with VAD therapy.<sup>
<xref ref-type="bibr" rid="bibr7-0897190011431635">7</xref>,<xref ref-type="bibr" rid="bibr8-0897190011431635">8</xref>,<xref ref-type="bibr" rid="bibr39-0897190011431635">39</xref>,<xref ref-type="bibr" rid="bibr47-0897190011431635">47</xref>
</sup> Bleeding can occur at any time after VAD implantation and may be related to systemic anticoagulation or acquired von Willebrand disease. It is difficult to compare bleeding rates between various clinical trials and reports due to differences in definitions and reporting. The most recent information on bleeding was reported in the INTERMACS registry. Similar bleeding rates were noted during the first year of therapy between patients receiving HeartMate II and those with a first-generation VAD (44.4% vs 38.5%, respectively; <italic>P</italic> = .1931).<sup>
<xref ref-type="bibr" rid="bibr39-0897190011431635">39</xref>
</sup> </p>
<p>Bleeding after VAD implantation has been defined as bleeding loss serious enough to necessitate returning the patient to the operative room or to cause death (eg, cardiac tamponade).<sup>
<xref ref-type="bibr" rid="bibr8-0897190011431635">8</xref>
</sup> Immediate postoperative bleeding may be related to adhesions, cannulation sites, or coagulopathy and in many causes can be controlled using blood products or hemostatic agents, such as aminocaproic acid. Desmopressin acetate, a synthetic analogue of arginine vasopressin, is also administered to control bleeding by increasing factor VIII and von Willebrand factor (vWF) levels. Protamine sulfate should be considered if bleeding is associated with intraoperative use of heparin. </p>
<p>Clinically significant bleeding was defined in another study as an episode of coagulopathy, or bleeding of the mediastinum pocket, thorax, or gastrointestinal system that results in death, the need for reoperation, hospitalization, or transfusions of red blood cells post implant.<sup>
<xref ref-type="bibr" rid="bibr47-0897190011431635">47</xref>
</sup> Common bleeding issues that occur after the immediate postoperative period include excessive epistaxis, gastrointestinal bleeding, vaginal bleeding, cuts or other trauma, and complications after outpatient procedures. Traumatic injuries can be serious and life threatening, even if the trauma does not directly affect the VAD. Major or clinically significant bleeding may require transfusion of blood or blood products, administration of recombinant factor VIIa, or emergent procedure or surgery. Minor bleeding can usually be managed with manual pressure to achieve hemostasis and subsequent adjustment in pharmacologic anticoagulation. </p>
<p>Anticoagulation with warfarin, in combination with aspirin therapy, is required postoperatively for most VADs to prevent thromboembolism and hemolysis. Goal international normalized ratio (INR) varies based on manufacturers' recommendations and patients' individual situations. However, it should be noted that significant bleeding can occur with elevated, normal, or low INR values. </p>
<p>A recently identified potential source of post-VAD implantation bleeding is an acquired von Willebrand syndrome.<sup>
<xref ref-type="bibr" rid="bibr59-0897190011431635">59</xref>
<xref ref-type="bibr" rid="bibr60-0897190011431635"/>
<xref ref-type="bibr" rid="bibr61-0897190011431635"/>–<xref ref-type="bibr" rid="bibr62-0897190011431635">62</xref>
</sup> In a study of 26 patients implanted with a HeartMate II LVAD, all subjects developed von Willebrand syndrome type 2 after implantation that was reversible on explant.<sup>
<xref ref-type="bibr" rid="bibr61-0897190011431635">61</xref>
</sup> One prospective multicenter study examined the characteristics of von Willebrand syndrome in patients implanted with a continuous flow LVAD.<sup>
<xref ref-type="bibr" rid="bibr62-0897190011431635">62</xref>
</sup> All patients demonstrated a significant reduction in high-molecular-weight (HMW) multimers of vWF and impaired vWF platelet-binding ability. While the cause is unknown, it has been hypothesized that the shear stress of the continuous flow VAD may cause proteolysis of the HWM multimers.<sup>
<xref ref-type="bibr" rid="bibr62-0897190011431635">62</xref>
<xref ref-type="bibr" rid="bibr63-0897190011431635"/>–<xref ref-type="bibr" rid="bibr64-0897190011431635">64</xref>
</sup> </p>
<p>Hemolysis occurs when red blood cells traumatically lyse as they pass through the VAD and is strongly related to platelet activation. Patients may develop either a symptomatic or asymptomatic hemolytic anemia and may exhibit signs of fatigue, dark tea-colored urine, or icterus. The management of hemolysis includes close monitoring and possible addition of dipyridamole to current aspirin therapy to decrease platelet adhesion. Recent data suggest this complication occurs at a rate of 1.2% to 3%<sup>
<xref ref-type="bibr" rid="bibr39-0897190011431635">39</xref> </sup>and is less common in the axial flow pumps<sup>
<xref ref-type="bibr" rid="bibr25-0897190011431635">25</xref>
</sup>. </p>
</sec>
<sec id="section13-0897190011431635">
<title>Neurologic events</title>
<p>Neurological dysfunction, specifically as a result of stroke, can significantly affect survival and ability to perform activities of daily living.<sup>
<xref ref-type="bibr" rid="bibr65-0897190011431635">65</xref>,<xref ref-type="bibr" rid="bibr66-0897190011431635">66</xref>
</sup> VADs are susceptible to thromboembolic events due to the foreign surfaces of the VAD that can activate platelets and the coagulation cascade. Turbulent blood flow can also increase the risk of thrombus formation.<sup>
<xref ref-type="bibr" rid="bibr13-0897190011431635">13</xref>
</sup> Newer generations of VADs may reduce the risk of thromboembolism by utilizing textured coatings and only one moving part. Venous thromboembolism in this patient population mainly results in embolic stroke and transient ischemic attacks. Another neurologic adverse effect from VAD therapy is hemorrhagic stroke. The REMATCH trial reported that 24% of patients implanted with the HeartMate XVE experienced a stroke, transient ischemic attack, or toxic encephalopathy.<sup>
<xref ref-type="bibr" rid="bibr7-0897190011431635">7</xref>
</sup> More recent stroke rates in the INTERMACS registry were 6.5% for patients with a HeartMate II and 5.3% for patients with a first-generation devices (<italic>P</italic> = .3821).<sup>
<xref ref-type="bibr" rid="bibr39-0897190011431635">39</xref>
</sup> Other neurological dysfunction (including transient ischemic attacks) occurred with a frequency of 4.1% and 7.7%, respectively (<italic>P</italic> = .0071). Strategies to prevent neurologic complications include VAD selection, prevention of infection which result in platelet activation, BP control, and careful monitoring of anticoagulation.<sup>
<xref ref-type="bibr" rid="bibr67-0897190011431635">67</xref>,<xref ref-type="bibr" rid="bibr68-0897190011431635">68</xref> </sup>Treatment of stroke in patients with a VAD may include intracranial pressure monitoring and possible surgical intervention for clot removal or cerebral decompression with ventriculostomy. </p>
</sec>
<sec id="section14-0897190011431635">
<title>RV failure</title>
<p>RV or right HF after implantation of a LVAD can significantly impact morbidity and mortality.<sup>
<xref ref-type="bibr" rid="bibr69-0897190011431635">69</xref>,<xref ref-type="bibr" rid="bibr70-0897190011431635">70</xref>
</sup> Although some patients may have some degree of right HF prior to VAD surgery, RV failure does not become evident until after surgery when an imbalance develops between the function of the newly supported left ventricle and failing right ventricle. Improved left ventricular function increases forward flow of blood into circulation, which may increase venous return to the heart beyond what the right ventricle can manage. Other factors that contribute to the decline in RV function after LVAD insertion include myocardial stunning, ischemia, arrhythmias, and increased pulmonary vascular resistance.<sup>
<xref ref-type="bibr" rid="bibr71-0897190011431635">71</xref> </sup>Right ventricular failure can affect LVAD filling, resulting in lower VAD flow rates (which is an equivalent measurement to cardiac output), and increase a patient's risk for hemorrhage and kidney failure. The incidence of RV failure after LVAD implantation in the INTERMACS registry ranged from 11.8% to 14.8%.<sup>
<xref ref-type="bibr" rid="bibr39-0897190011431635">39</xref>
</sup> Management of RV failure includes administration of inotropes, use of inhaled nitric oxide or vasodilators for pulmonary hypertension, and diuretics. If drug therapy is ineffective, the patient may need implantation of RVAD for either temporary or long-term support. Patients with persistent pulmonary hypertension after VAD implantation may require treatment with the phosphodiesterase inhibitor sildenafil.<sup>
<xref ref-type="bibr" rid="bibr72-0897190011431635">72</xref>
</sup>
</p>
</sec>
<sec id="section15-0897190011431635">
<title>Multiple organ failure</title>
<p>Multiple organ failure is a serious acute and long-term complication that is a main contributor to mortality among patients who receive VAD therapy.<sup>
<xref ref-type="bibr" rid="bibr73-0897190011431635">73</xref>
<xref ref-type="bibr" rid="bibr74-0897190011431635"/>
<xref ref-type="bibr" rid="bibr75-0897190011431635"/>–<xref ref-type="bibr" rid="bibr76-0897190011431635">76</xref>
</sup> Unfortunately, these patients may already have preoperative renal or hepatic dysfunction as a result of severe HF.<sup>
<xref ref-type="bibr" rid="bibr33-0897190011431635">33</xref>,<xref ref-type="bibr" rid="bibr73-0897190011431635">73</xref>
</sup> They may also be on mechanical ventilation and have pulmonary compromise. Several factors have been implicated as the source of multiple organ failure after VAD implantation, including activation of inflammatory responses and release of cytokines and chemical mediators such as nitric oxide, endothelin, and prostaglandins that affect organ perfusion and cause damage.<sup>
<xref ref-type="bibr" rid="bibr75-0897190011431635">75</xref>
</sup> Second, surgery may increase the risk of infection resulting in activation of inflammatory responses. Finally, changes in cardiac output, hemodilution, hypothermia, and massive blood transfusions may further reduce hepatic and renal perfusion. The incidence of multiple organ failure in the INTERMACS registry was 10.1% to 12.4% for renal dysfunction, 5.3% to 6.5% for hepatic dysfunction, and 20% to 25.4% for respiratory failure.<sup>
<xref ref-type="bibr" rid="bibr39-0897190011431635">39</xref>
</sup> </p>
<p>Other potential causes of postoperative acute renal failure include the need for emergent VAD implantation, length of time on cardiopulmonary bypass, and higher intraoperative blood loss.<sup>
<xref ref-type="bibr" rid="bibr74-0897190011431635">74</xref>
</sup> Acute renal failure within 60 days of VAD implantation is a strong predictor of 1-year mortality, increasing the mortality risk 3-fold even after controlling for other baseline patient characteristics and adverse events (hazard ratio 2.96, <italic>P</italic> = .023).<sup>
<xref ref-type="bibr" rid="bibr38-0897190011431635">38</xref>
</sup> Acute renal dysfunction can further increase the risk for infections, liver injury, right ventricular failure, and ventricular arrhythmias in those patients who require dialysis.<sup>
<xref ref-type="bibr" rid="bibr73-0897190011431635">73</xref>
</sup> </p>
<p>It has been demonstrated that patients with preoperative renal and liver failure have an increased risk of developing further organ failure in the immediate and long-term postoperative period.<sup>
<xref ref-type="bibr" rid="bibr38-0897190011431635">38</xref> </sup>Optimization of these conditions prior to VAD implantation through the use of diuretics and inotropes has been found to improve postoperative outcomes and overall mortality.<sup>
<xref ref-type="bibr" rid="bibr73-0897190011431635">73</xref>
</sup> Preoperative optimization with renal replacement therapy may also be an option for severe hypervolemia and renal failure.</p>
<p>After surgery, prompt identification and aggressive treatment of renal and liver dysfunction may aid in the recovery of the patient. Patients must be monitored daily for changes in renal and hepatic function and medications adjusted accordingly. Urine output, serum electrolytes, and creatinine are commonly monitored to assess for acute renal dysfunction. Treatments include the use of diuretics or inotropic support, fluid management, and renal replacement therapies.<sup>
<xref ref-type="bibr" rid="bibr36-0897190011431635">36</xref>,<xref ref-type="bibr" rid="bibr77-0897190011431635">77</xref>
</sup> Hepatic dysfunction is commonly manifested by elevations in liver function tests, such as bilirubin, transaminases, and coagulation panels. Treatment of hepatic failure is primarily supportive and includes decreasing or eliminating hepatotoxic medications. In patients with hepatic dysfunction, adjustment in anticoagulation therapy is also required to avoid bleeding complications. </p>
<p>Patients who require VAD support for long periods of time, particularly for the indication of DT, are at risk for developing renal and liver failure. Even after hospital discharge, frequent monitoring of fluid status and organ function in combination with physical assessment is required. Management of fluid balance is important in order to prevent organ system failure or slow its progression. Consultations with nephrology or hepatology may be necessary in the treatment of these patients.<sup>
<xref ref-type="bibr" rid="bibr77-0897190011431635">77</xref>
</sup>
</p>
<p>The lungs are another set of organs that can be adversely affected after VAD implantation. Early respiratory failure, defined as the need for reintubation or tracheostomy within the first 60 days after surgery, has been associated with an increased mortality rate.<sup>
<xref ref-type="bibr" rid="bibr47-0897190011431635">47</xref>
</sup> While the mechanism is unclear, it has been hypothesized that periods of diminished tissue oxygenation leads to increased right ventricular stress. Alternatively, the known risks associated with mechanical ventilation may explain the increase in mortality. Later generation VADs may have lower rates of respiratory complications compared to first-generation devices due to their smaller size and decreased presence in the thoracic or pre-peritoneal space. In the INTERMACS registry, the patients who received the HeartMate II demonstrated a significantly lower rate of respiratory failure compared to patients who received a first-generation device (20.1% and 25.4%, respectively; <italic>P</italic> = .0084).<sup>
<xref ref-type="bibr" rid="bibr39-0897190011431635">39</xref>
</sup> </p>
</sec>
<sec id="section16-0897190011431635">
<title>Arrhythmias</title>
<p>The risk for serious arrhythmias continues in patients with end-stage HF even after receiving LVAD support.<sup>
<xref ref-type="bibr" rid="bibr78-0897190011431635">78</xref>,<xref ref-type="bibr" rid="bibr79-0897190011431635">79</xref>
</sup> These arrhythmias may be atrial or ventricular and include atrial fibrillation, supraventricular tachycardia, ventricular tachycardia, and ventricular fibrillation.<sup>
<xref ref-type="bibr" rid="bibr78-0897190011431635">78</xref>
</sup> Arrhythmias, particularly ventricular arrhythmias, occur in approximately 27% to 38% of patients after VAD implantation.<sup>
<xref ref-type="bibr" rid="bibr39-0897190011431635">39</xref> </sup>They can occur in the immediate postoperative period due to changes in the electrical conduction of the atrioventricular and sinoatrial nodes from surgical manipulation, inflammation, myocyte remodeling, previous or a newly acquired myocardial scar, or from the use of inotropic agents.<sup>
<xref ref-type="bibr" rid="bibr78-0897190011431635">78</xref>,<xref ref-type="bibr" rid="bibr79-0897190011431635">79</xref>
</sup>
</p>
<p>Patients with a VAD may tolerate arrhythmias better than others as the device provides hemodynamic stability and end-organ perfusion through ventricular support,<sup>
<xref ref-type="bibr" rid="bibr78-0897190011431635">78</xref>
<xref ref-type="bibr" rid="bibr79-0897190011431635"/>–<xref ref-type="bibr" rid="bibr80-0897190011431635">80</xref>
</sup> but symptomatic patients with clinical signs of hypoperfusion should always be treated immediately. Treatment options include administration of antiarrhythmic agents (ie, amiodarone, lidocaine, beta-blockers), normalization of serum electrolyte levels, weaning off pressor support, use of antitachycardia pacing (ATP), and direct current cardioversion or defibrillation.<sup>
<xref ref-type="bibr" rid="bibr79-0897190011431635">79</xref>
</sup> A combination of these interventions may be necessary for rhythm control. As patients with ischemic cardiomyopathy are at greatest risk for postoperative ventricular arrhythmias, it has been recommended that preoperative antiarrhythmic therapy should be continued after VAD implantation, as well as ICD if present.<sup>
<xref ref-type="bibr" rid="bibr78-0897190011431635">78</xref>
</sup> </p>
<p>In cases where arrhythmias continue after the immediate postoperative period, further interventions and long-term oral antiarrhythmic therapy with amiodarone or beta-blockers may be necessary. Possible treatment options of intractable arrhythmias include placement of a pacemaker with ATP capabilities and ICD. Radiofrequency ablation is an intervention that may be attempted in patients with frequent arrhythmias and ICD firings.<sup>
<xref ref-type="bibr" rid="bibr80-0897190011431635">80</xref>
</sup>
</p>
</sec>
<sec id="section17-0897190011431635">
<title>Device malfunction</title>
<p>VAD malfunction and failure is a complication that can be life threatening and is becoming more important as VADs are being used for longer time periods. Complications can arise from any VAD component, ranging from the portable controller to the pump itself. Device failure after 1 year occurred in 17.9% of patients who received a LVAD for DT in the REMATCH trial and was the second most common cause of death.<sup>
<xref ref-type="bibr" rid="bibr7-0897190011431635">7</xref> </sup>As technology and engineering continues to advance, newer generation continuous flow devices may decrease the risk of malfunction due to fewer moving parts and improved long-term durability.<sup>
<xref ref-type="bibr" rid="bibr35-0897190011431635">35</xref>
</sup> A study of 195 patients with first-generation VAD support found a device malfunction rate of 9.2% (95% CI 5.7%-13.8%),<sup>
<xref ref-type="bibr" rid="bibr47-0897190011431635">47</xref>
</sup> while more recent data reported a device replacement rate of 1.2% in patients with a second-generation VAD (n = 169).<sup>
<xref ref-type="bibr" rid="bibr39-0897190011431635">39</xref>
</sup>
</p>
<p>Limited options exist for treatment of VAD malfunction and failure. The extent of repair is dependent on the VAD type and location of damage. Repair of external components, such as the driveline, may be available in some cases of pump damage. Exchange of the VAD pump, such as in the cases of uncontrolled infection or pump failure, may be possible depending on the patient's surgical risk and the ability to transport the patient to the implant center.<sup>
<xref ref-type="bibr" rid="bibr81-0897190011431635">81</xref>,<xref ref-type="bibr" rid="bibr82-0897190011431635">82</xref>
</sup> In the situation of pump failure, first-generation devices have a backup hand pump that the patient or caregiver uses to maintain forward blood flow and hemodynamic stability. However, this may lead to a low-stroke volume and the need for inotropic therapy to support BP and cardiac output prior to surgical exchange. Anticoagulation with heparin should also be considered preoperatively (while holding warfarin and aspirin therapies) to lower the risk of pump thromboembolism due to low stroke volume.</p>
<p>Unfortunately, device exchange may not be an option for all patients with a VAD. The treatments for patients who are not candidates for pump exchange differ depending on their goal of VAD therapy. BTT patients may be maintained with medical therapy until a suitable heart becomes available. BTR patients may be completely explanted of the device if cardiac function is adequate to maintain survival. For DT patients, extensive end-of-life discussion must occur with patients, families, and support persons in order to make patient-specific decisions regarding continued care and possible withdrawal of support.<sup>
<xref ref-type="bibr" rid="bibr83-0897190011431635">83</xref>,<xref ref-type="bibr" rid="bibr84-0897190011431635">84</xref>
</sup>
</p>
</sec>
</sec>
</sec>
<sec id="section18-0897190011431635">
<title>Pharmacotherapy</title>
<p>There are no specific guidelines for pharmacotherapy management of patients with a VAD but treatment generally follows accepted HF guidelines.<sup>
<xref ref-type="bibr" rid="bibr2-0897190011431635">2</xref>,<xref ref-type="bibr" rid="bibr3-0897190011431635">3</xref>
</sup> Agents used for HF should be resumed as soon as the patient has stabilized postoperatively (<xref ref-type="table" rid="table4-0897190011431635">Table 4</xref>). Guidelines emphasize the use of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, beta-blockers, and aldosterone antagonists in combination with diuretics for management of HF symptoms. Details related todosing, monitoring, and morbidity/mortality benefits with the various neurohormonal agents are described elsewhere.<sup>
<xref ref-type="bibr" rid="bibr2-0897190011431635">2</xref>
</sup> Medication management must always be tailored to each individual patient as patients with HF commonly have other complicating medical conditions. Along with utilizing HF guidelines, there are 2 additional areas of focus in the pharmacologic management of patients receiving VAD therapy: infection and anticoagulation.</p>
<table-wrap id="table4-0897190011431635" position="float">
<label>Table 4.</label>
<caption>
<p>Pharmacologic Agents Recommended in Heart Failure<sup>
<xref ref-type="bibr" rid="bibr2-0897190011431635">2</xref>,<xref ref-type="bibr" rid="bibr94-0897190011431635">94</xref>,<xref ref-type="bibr" rid="bibr95-0897190011431635">95</xref>
</sup>
</p>
</caption>
<graphic alternate-form-of="table4-0897190011431635" xlink:href="10.1177_0897190011431635-table4.tif"/>
<table>
<thead>
<tr>
<th>Pharmacologic Class</th>
<th>Recommended Agents </th>
<th>Utility in HF Treatment<sup>
<xref ref-type="bibr" rid="bibr93-0897190011431635">93</xref>
</sup>
</th>
<th>Recommendation/Level of Evidence<sup>
<xref ref-type="bibr" rid="bibr93-0897190011431635">93</xref>
</sup>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angiotensin-converting enzyme inhibitors (ACEIs) </td>
<td>Captopril, enalapril, lisinopril, ramipril, trandolopril</td>
<td>Decrease mortality, reduce hospitalizations (RRR 15%-27% in death and hospitalization) </td>
<td>ESC: Class Ia, Level A; ACCF/ AHA: Class I, Level A</td>
</tr>
<tr>
<td>Angiotensin II receptor blockers </td>
<td>Candesartan, valsartan </td>
<td>For use in patients intolerant to ACEI</td>
<td>ESC: Class Ia, Level A&amp;B; ACCF/ AHA: Class I, Level A </td>
</tr>
<tr>
<td>Nitrates/hydralazine</td>
<td>Isosorbide dinitrate, isosorbide mononitrate, nitroglycerin patch/ hydralazine</td>
<td>Reduce hospitalization (RRR 33%), increase exercise capacity</td>
<td>ESC: Class IIa, level A&amp;B; ACCF/ AHA: Class IIa, level B</td>
</tr>
<tr>
<td>Beta-blockers</td>
<td>Bisoprolol, carvedilol, metoprolol succinate, nebivolol</td>
<td>Reduce mortality (RRR ∼34%), reduce hospitalizations by 28-36% </td>
<td>ESC: Class Ia, Level A; ACCF/ AHA: Class 1, Level A</td>
</tr>
<tr>
<td>Aldosterone antagonists</td>
<td>eplerenone, spironolactone</td>
<td>Decrease mortality by 30% and hospitalizations by 35% in patients with EF ≤35% and NYHA class III/IV when added to traditional therapy<sup>
<xref ref-type="bibr" rid="bibr94-0897190011431635">94</xref>
</sup>
</td>
<td>ESC: Class Ia, Level B; ACCF/ AHA; Class I, Level B</td>
</tr>
<tr>
<td>Digitalis </td>
<td>Digitalis</td>
<td>Decrease hospitalizations </td>
<td>ESC: Class I, Level C &amp; Class II, Level B; ACCF/ AHA: Class IIa, Level B </td>
</tr>
<tr>
<td>Loop and thiazide diuretics</td>
<td>Loop: bumetinide, furosemide, torsemide; thiazide: chlorothiazide, metolazone</td>
<td>Improve HF symptoms </td>
<td>ESC: Class I, Level B; ACCF/ AHA: Class I, Level B </td>
</tr>
<tr>
<td>Antiarrythmics </td>
<td>Amiodarone, dofetilide</td>
<td>Preferred in HF </td>
<td>N/A</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn29-0897190011431635">
<p>Abbreviations: NYHA, New York Heart Association; ESC, European Society of Cardiology; ACCF/AHA, American College of Cardiology Foundation/American Heart Association; EF, ejection fraction; HF, heart failure; RRR, relative risk reduction.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Infection is of particular concern to both patient and practitioner as it is a major source of morbidity and mortality. The reported incidence of infection ranges from 25% to 50% and the risk increases over time.<sup>
<xref ref-type="bibr" rid="bibr54-0897190011431635">54</xref>
</sup> One reason for the frequency of infection is the external driveline site, a unique conduit for infection in these patients. As a preventive measure, it is extremely important for the patient and caregiver to use sterile technique when performing daily dressing changes to the site. An antiseptic solution is used to cleanse the exit site and the dressing is held in place with a binder or abdominal wrap to immobilize the driveline. If the patient develops a driveline site infection, the bacteria may seed the pocket, pump, bloodstream, and the heart. </p>
<p>VAD-related infection has been shown to increase the risk of sepsis (defined as systemic inflammatory response with positive cultures) and septic shock which further increases the risk of morbidity and mortality.<sup>
<xref ref-type="bibr" rid="bibr85-0897190011431635">85</xref>
</sup> In one report, the majority of device-related infections occurred between postoperative weeks 2 to 6, and it has been postulated that this may be a high-risk time for infections.<sup>
<xref ref-type="bibr" rid="bibr54-0897190011431635">54</xref>
</sup> Diagnosis is based on signs and symptoms, cultures (blood, fluid, and tissue), and imaging (computed tomography [CT] scan, ultrasound).<sup>
<xref ref-type="bibr" rid="bibr87-0897190011431635">87</xref>
</sup> Commonly reported signs and symptoms are fever, leukocytosis, vasodilation, embolism, drainage, abnormalities around the exit site (ie, bleeding, pain/tenderness, erythema, skin or wound necrosis), and cachexia.<sup>
<xref ref-type="bibr" rid="bibr54-0897190011431635">54</xref>,<xref ref-type="bibr" rid="bibr56-0897190011431635">56</xref>
</sup> When a patient presents with signs or symptoms of infection, the VAD driveline exit site should be cultured and empiric antibiotics started promptly. Depending on the type of infection, surgical intervention may be required in combination with antibiotics. <italic>Staphylococcus</italic>, <italic>Enterococcus</italic>, <italic>Pseudomonas</italic>, and <italic>Candida</italic> species are the most commonly implicated microbes and drug therapy should cover these organisms to prevent or treat VAD-related infections.<sup>
<xref ref-type="bibr" rid="bibr56-0897190011431635">56</xref>,<xref ref-type="bibr" rid="bibr85-0897190011431635">85</xref>,<xref ref-type="bibr" rid="bibr86-0897190011431635">86</xref>
</sup> Vancomycin, a third-generation cephalosporin (eg, ceftazidime) or a fluoroquinolone (eg, ciprofloxacin), and an antifungal agent should be the initial empiric regimen.<sup>
<xref ref-type="bibr" rid="bibr54-0897190011431635">54</xref>
</sup> Antimicrobial therapy should be de-escalated when culture results become available and for most infections, therapy is usually continued for 3 to 4 weeks.<sup>
<xref ref-type="bibr" rid="bibr56-0897190011431635">56</xref>
</sup> Proper wound care is also extremely important, including good blood glucose control and proper nutrition to facilitate wound healing.<sup>
<xref ref-type="bibr" rid="bibr87-0897190011431635">87</xref>
</sup>
</p>
<p>A method to minimize early postoperative infection is the administration of broad-spectrum prophylactic therapy preoperatively.<sup>
<xref ref-type="bibr" rid="bibr85-0897190011431635">85</xref>
</sup> Our facility provides prophylaxis with ciprofloxacin, vancomycin, fluconazole, and rifampin started immediately preoperative and continued postoperatively for 48 hours. As with other implanted medical devices, infections can potentially affect and infect the VAD. Therefore, all patients with a VAD should receive prophylactic antibiotics for invasive procedures (including dental work or colonoscopy) for the duration of VAD support. </p>
<p>Prevention of thromboembolic complications with anticoagulants is the second major area of pharmacotherapy unique to a VADs. Despite systemic anticoagulation, the risk of a thromboembolic event is approximately 30%.<sup>
<xref ref-type="bibr" rid="bibr88-0897190011431635">88</xref>
</sup> Mechanisms of clot formation include contact between blood and foreign surfaces of the VAD, fluctuating velocities of blood flow, blood stasis in the heart, septic complications, and insufficient anticoagulation. Anticoagulation therapy generally consists of a vitamin K antagonist (eg, warfarin) and an antiplatelet agent. Each manufacturer has specific anticoagulation recommendations for its device (<xref ref-type="table" rid="table5-0897190011431635">Table 5</xref>).<sup>
<xref ref-type="bibr" rid="bibr91-0897190011431635">91</xref>
<xref ref-type="bibr" rid="bibr92-0897190011431635"/>–<xref ref-type="bibr" rid="bibr93-0897190011431635">93</xref>
</sup> The decision of which INR goal to target is determined by the cardiac surgeon and is based upon several factors, most significantly the patient's relative risk of hemorrhage or thrombosis. The majority of device manufacturers recommend a goal INR of 2 to 2.5, with Thoratec IVAD recommending a goal INR of 2.5 to 3.<sup>
<xref ref-type="bibr" rid="bibr91-0897190011431635">91</xref>
<xref ref-type="bibr" rid="bibr92-0897190011431635"/>–<xref ref-type="bibr" rid="bibr93-0897190011431635">93</xref>
</sup> Individualization of this regimen does occur based on a patient's past history of bleeding. </p>
<table-wrap id="table5-0897190011431635" position="float">
<label>Table 5.</label>
<caption>
<p>Anticoagulation Recommendations for Common FDA-Approved Devices<sup>
<xref ref-type="table-fn" rid="table-fn31-0897190011431635">a</xref>,<xref ref-type="bibr" rid="bibr88-0897190011431635">88</xref>
<xref ref-type="bibr" rid="bibr89-0897190011431635"/>
<xref ref-type="bibr" rid="bibr90-0897190011431635"/>
<xref ref-type="bibr" rid="bibr91-0897190011431635"/>
<xref ref-type="bibr" rid="bibr92-0897190011431635"/>–<xref ref-type="bibr" rid="bibr93-0897190011431635">93</xref>
</sup>
</p>
</caption>
<graphic alternate-form-of="table5-0897190011431635" xlink:href="10.1177_0897190011431635-table5.tif"/>
<table>
<thead>
<tr>
<th>Ventricular Assist Device</th>
<th>Aspirin</th>
<th>Dipyridamole</th>
<th>Warfarin (Goal INR)</th>
<th>Unfractionated Heparin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heartmate XVE<sup>
<xref ref-type="table-fn" rid="table-fn32-0897190011431635">b</xref>
</sup>
</td>
<td>81 mg daily; initiate after post-operative bleeding subsided</td>
<td>None</td>
<td>None</td>
<td>None</td>
</tr>
<tr>
<td>Heartmate II<sup>
<xref ref-type="table-fn" rid="table-fn32-0897190011431635">b</xref>
</sup>
</td>
<td>81 mg daily</td>
<td>75 mg TID<sup>
<xref ref-type="table-fn" rid="table-fn33-0897190011431635">c</xref>
</sup>
</td>
<td>1.5-2; 2-2.5; 2-3<sup>
<xref ref-type="table-fn" rid="table-fn34-0897190011431635">d</xref>
</sup>
</td>
<td>None</td>
</tr>
<tr>
<td>Thoratec IVAD<sup>
<xref ref-type="table-fn" rid="table-fn32-0897190011431635">b</xref>
</sup>
</td>
<td>81 mg daily at several centers in patients with &gt;30 days of VAD support for platelet counts above 300 TH/mm<sup>3</sup>
</td>
<td>None</td>
<td>2.5-3.5</td>
<td>Used for bridging therapy; titrate dose to maintain aPTT approximately 1.5× control</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn30-0897190011431635">
<p>Abbreviations: VAD, ventricular assist device; IVAD, implantable ventricular assist device; INR, international normalized ratio; aPTT, activated partial thromboplastin time; TID, thrice daily.</p>
</fn>
<fn id="table-fn31-0897190011431635">
<p>
<sup>a</sup> Modifications to anticoagulation may occur based on individual patient needs and per VAD center's discretion.</p>
</fn>
<fn id="table-fn32-0897190011431635">
<p>
<sup>b</sup> Thoratec Corporation, Pleasanton, California</p>
</fn>
<fn id="table-fn33-0897190011431635">
<p>
<sup>c</sup> Dipyridamole recommended by manufacturer but not currently used in many VAD centers.</p>
</fn>
<fn id="table-fn34-0897190011431635">
<p>
<sup>d</sup> Recent data provide evidence of lower hemorrhage incidence with an INR goal 1.5 to -2.5 with low risk of thrombosis.<sup>
<xref ref-type="bibr" rid="bibr89-0897190011431635">89</xref>,<xref ref-type="bibr" rid="bibr90-0897190011431635">90</xref>
</sup> Centers generally select a goal of 1.5 to 2 for patients with history of bleeding and 2 to 2.5 for patients with history of thrombosis. Device manufacturer continues to recommend INR goal of 2 to 3 at this time.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Investigators evaluated the risk of thromboembolism and hemorrhage related to the level of anticoagulation in 331 patients implanted with the HeartMate II LVAD.<sup>
<xref ref-type="bibr" rid="bibr89-0897190011431635">89</xref>
</sup> Thrombosis in this study was defined as ischemic stroke or clinically significant thromboses to the VAD pump. Hemorrhage was defined as hemorrhagic stroke or bleeding significant enough to require at least 2 units of packed red blood cells or surgical exploration. Most patients were anticoagulated with warfarin and received aspirin, with approximately half receiving concomitant dipyridamole. A total of 1294 INR values were collected; the median INR was 2.1 at time of hospital discharge and 1.9 at 6 months. Thromboses occurred in 3.3% of patients, particularly when the INR was &lt;1.5. Hemorrhagic stroke occurred in 2.1% of patients, particularly when the INR was &gt;3. Compared to thrombotic events or hemorrhagic strokes, the incidence of bleeding that required transfusion was significantly higher (15.4%; <italic>P</italic> &lt; .001). Hemorrhagic events (most commonly gastrointestinal bleeding) occurred across all INR ranges but the highest event rates occurred when the INR was &gt;2.5. This study provides evidence that the risk of hemorrhage is greater than the risk of thrombosis in patients implanted with the HeartMate II. Therefore, titrating warfarin therapy to achieve a lower INR goal of 1.5 to 2.5 when used in combination with aspirin is an appropriate recommendation to minimize the risk of both hemorrhagic and thrombotic complications. Based on this study, some VAD centers have lowered their INR goals to 1.5 to 2 to decrease the risk of bleeding associated with a higher INR target.<sup>
<xref ref-type="bibr" rid="bibr39-0897190011431635">39</xref>,<xref ref-type="bibr" rid="bibr90-0897190011431635">90</xref>
</sup> One single-center study reported a device thrombosis rate of 4.4% (2 of 45 patients) when warfarin therapy was adjusted to achieve an INR goal of 1.5 to 2.<sup>
<xref ref-type="bibr" rid="bibr90-0897190011431635">90</xref> </sup>Further research is needed to examine the outcomes associated with lower INR goals.</p>
<p>For most devices, aspirin is combined with warfarin to further prevent thromboembolism and reduce platelet adhesion to the device. Aspirin monotherapy is reserved for only those devices with heparin-coated blood contacting surfaces and those with textured surfaces that allow for endothelialization.<sup>
<xref ref-type="bibr" rid="bibr96-0897190011431635">96</xref>
</sup> The HeartMate XVE is the only FDA-approved device that recommends aspirin without warfarin therapy and has similar bleeding and embolic rates as other VADs <sup>
<xref ref-type="bibr" rid="bibr39-0897190011431635">39</xref>
</sup> Compared to the HeartMate II<sup>b</sup>, a device which requires warfarin and aspirin therapy, there were no statistically significant differences in bleeding (<italic>P</italic> = .1931), hemorrhagic stroke (<italic>P</italic> = .6986), embolic stroke (<italic>P</italic> = .6323), or venous thromboembolism (<italic>P</italic> = .1820) between the 2 devices. </p>
<p>Low-molecular-weight heparin (LMWH) has been studied with antiplatelet agents in both the immediate postoperative period<sup>
<xref ref-type="bibr" rid="bibr97-0897190011431635">97</xref>
</sup> and as an alternative to warfarin.<sup>
<xref ref-type="bibr" rid="bibr98-0897190011431635">98</xref>
</sup> Trials have been small in nature and inconclusive. In one study examining 8 postoperative VAD patients receiving nadroparin as an alternative to unfractionated heparin, there were no major bleeding events, 3 incidences of minor bleeding, and 4 incidences of thrombotic events.<sup>
<xref ref-type="bibr" rid="bibr97-0897190011431635">97</xref>
</sup> Nadroparin was given twice daily to achieve a target antifactor Xa peak level of 0.4 ± 0.1 U/mL and patients received concomitant aspirin and dipyridamole therapy. A similar study examined 10 patients receiving triple antiplatelet therapy (aspirin, clopidogrel, and dipyridamole) in combination with enoxaparin 1 mg/kg twice daily for more than 3 weeks post VAD implantation.<sup>
<xref ref-type="bibr" rid="bibr98-0897190011431635">98</xref>
</sup> Four study patients died before receiving heart transplantation: one death was attributable to intestinal hemorrhage, one to hemorrhagic stroke, and the others to nonischemic or hemorrhagic complications. Larger trials are needed before formal recommendations can be made regarding the use of LMWH for anticoagulation in patients with a VAD. </p>
<p>There is no information currently available on the use of the new oral antithrombotics, dabigatran, and rivaroxaban, for anticoagulation in patients with a VAD. </p>
</sec>
<sec id="section19-0897190011431635">
<title>Nonpharmacologic Considerations</title>
<p>Similar to patients with HF, patients with VAD support are sensitive to fluid changes. After VAD implantation, patients must continue to follow fluid and sodium restrictions (generally &lt;2000 mg sodium/d). Because the VAD augments cardiac output, intravascular volume is particularly important; fluid status must be optimized to avoid situations of hypervolemia or dehydration. Patients are encouraged to drink 2 L of fluid daily in order to maintain intravascular fluid balance. </p>
<p>Patients are encouraged to participate in supervised cardiac rehabilitation programs and may be able to increase their physical fitness, lose solid weight, and increase exertional capacity.<sup>
<xref ref-type="bibr" rid="bibr99-0897190011431635">99</xref>
</sup> Patients are also encouraged to limit their alcohol intake, stop smoking, and maintain a healthy weight. From our experience, some patients with a VAD who are not transplant candidates due to weight have been able to increase their physical activity sufficiently to lose weight and qualify for transplantation.</p>
<p>Medical Centers that implant VADs have different policies regarding emergency care. Examples of VAD emergencies include a loss of power to the pump, broken wires, low flow (similar to a state of low cardiac output), a blocked tube, damage to the pump motor, or fluid in the filter or tube. An alarm will sound if the system is not working correctly. First-generation pneumatic VAD can be operated by an emergency hand pump after disconnection from the power source.<sup>
<xref ref-type="bibr" rid="bibr91-0897190011431635">91</xref>
</sup> There are no backup pumps for second- or third-generation continuous flow devices. Depending on the VAD center, external chest compressions may or may not be performed in situations of cardiopulmonary resuscitation. External chest compressions may compromise the aortic anastomosis, dislodge the VAD inflow tract, or damage the device itself.<sup>
<xref ref-type="bibr" rid="bibr92-0897190011431635">92</xref>
</sup>
</p>
</sec>
<sec id="section20-0897190011431635">
<title>Pharmacist Training and Education</title>
<p>Patients who receive VAD support interact with pharmacists in a variety of practice settings, including inpatient, ambulatory, and community pharmacies. Pharmacists are in a unique position to provide drug information and lifestyle education to this special patient population. Smoking cessation, vaccinations, and nutrition information are all opportunities for a pharmacist to make an impact on patient care beyond providing medication management.<sup>
<xref ref-type="bibr" rid="bibr100-0897190011431635">100</xref>
<xref ref-type="bibr" rid="bibr101-0897190011431635"/>–<xref ref-type="bibr" rid="bibr102-0897190011431635">102</xref>
</sup> Additionally, pharmacists may need to provide assistance in obtaining wound care supplies. Often this is completed through a home health care agency but is largely determined by insurance requirements. Supplies such as chlorhexidine are often considered to be a drug product by insurance companies and covered by the patient's pharmacy benefits manager, requiring these products to be obtained by prescription.</p>
<p>Patients with a VAD are traditionally assigned a coordinator. A VAD coordinator is a direct contact person for the patient, should any health care needs arise. These individuals have special training with VADs and are often able to troubleshoot mechanical problems or make adjustments to the device. Coordinators are a patient resource and advocate with varying backgrounds ranging from registered or advanced practice nurses, engineers, or perfusionists. They are heavily involved with patient care and are a primary contact for other health care professionals who have questions regarding issues with such patients. Pharmacists should develop a good working relationship with their patients' VAD coordinators as these medical professionals ultimately organize all the care VAD patients receive. Pharmacists can work with VAD coordinators and other members of the multidisciplinary team to ensure the use of appropriate drug therapy based on established HF guidelines. They can provide anticoagulation management, dose titration protocols, and manage patient drug therapy. A basic understanding of this unique therapy can further assist pharmacists in attending to the needs of patients with a VAD.</p>
</sec>
<sec id="section21-0897190011431635">
<title>Summary</title>
<p>With the increasing incidence of HF and shortage of viable organs, VADs have become a successful means to bridge patients until transplantation, allow for cardiac recovery, or become DT. The increasing VAD population requires pharmacists who interact with these patients to understand the relationship between HF, mechanical circulatory support device, and medications. Patients receiving VAD support will benefit from pharmacists who understand their complex drug therapies and can manage or prevent complications.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-0897190011431635">
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0897190011431635">
<p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0897190011431635">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roger</surname>
<given-names>VL</given-names>
</name>
<name>
<surname>Lloyd-Jones</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>RJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Heart disease and stroke statistics 2011 update: a report from the American Heart Association</article-title>. <source>Circulation</source>. <year>2011</year>;<volume>123</volume>:<fpage>e18</fpage>-<lpage>e209</lpage>. <comment>Epub 2010 Dec 15</comment>.</citation>
</ref>
<ref id="bibr2-0897190011431635">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hunt</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Abraham</surname>
<given-names>WT</given-names>
</name>
<name>
<surname>Chin</surname>
<given-names>MH</given-names>
</name>
<etal/>
</person-group>; <article-title>American College of Cardiology Foundation; American Heart Association. 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults</article-title>. <source>J Am Coll Cardiol</source>. <year>2009</year>;<volume>53</volume>:<fpage>e1</fpage>-<lpage>e90</lpage>.</citation>
</ref>
<ref id="bibr3-0897190011431635">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adams</surname>
<given-names>KF</given-names>
</name>
<name>
<surname>Lindenfeld</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Arnold</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Executive summary: HFSA 2006 comprehensive heart failure practice guidelines</article-title>. <source>J Card Fail</source>. <year>2006</year>;<volume>12</volume>(<issue>1</issue>):<fpage>10</fpage>-<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr4-0897190011431635">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feldman</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Menachemi</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Abraham</surname>
<given-names>WT</given-names>
</name>
<etal/>
</person-group>. <article-title>Management strategies for stage-D patients with acute heart failure</article-title>. <source>Clin Cardiol</source>. <year>2008</year>;<volume>31</volume>(<issue>7</issue>):<fpage>297</fpage>-<lpage>301</lpage>.</citation>
</ref>
<ref id="bibr5-0897190011431635">
<label>5</label>
<citation citation-type="other">
<collab collab-type="author">The Organ Procurement and Transplantation Network Web site</collab>. <ext-link ext-link-type="uri" xlink:href="http://www.optn.org">http://www.optn.org</ext-link>. <comment>Accessed March 12, 2010</comment>.</citation>
</ref>
<ref id="bibr6-0897190011431635">
<label>6</label>
<citation citation-type="other">
<collab collab-type="author">2008 Annual Report of the U.S</collab>. <comment>Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1998-2007. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD; United Network for Organ Sharing, Richmond, VA; University Renal Research and Education Association, Ann Arbor, MI</comment>.</citation>
</ref>
<ref id="bibr7-0897190011431635">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rose</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Gelijns</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Moskowitz</surname>
<given-names>AJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Long-term use of a left ventricular assist device for end-stage heart failure</article-title>. <source>N Eng J Med</source>. <year>2001</year>;<volume>345</volume>(<issue>20</issue>):<fpage>1435</fpage>-<lpage>1443</lpage>.</citation>
</ref>
<ref id="bibr8-0897190011431635">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frazier</surname>
<given-names>OH</given-names>
</name>
<name>
<surname>Rose</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Oz</surname>
<given-names>MC</given-names>
</name>
<etal/>
</person-group>. <article-title>Multicenter clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation</article-title>. <source>J Thorac Cardiovasc Surg</source>. <year>2001</year>;<volume>122</volume>:<fpage>1186</fpage>-<lpage>1195</lpage>.</citation>
</ref>
<ref id="bibr9-0897190011431635">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Birks</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Tansley</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Hardy</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Left ventricular assist device and drug therapy for the reversal of heart failure</article-title>. <source>N Engl J Med</source>. <year>2006</year>;<volume>355</volume>:<fpage>1873</fpage>-<lpage>1884</lpage>.</citation>
</ref>
<ref id="bibr10-0897190011431635">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sayer</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Naka</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Jorde</surname>
<given-names>UP</given-names>
</name>
</person-group>. <article-title>Ventricular assist device therapy</article-title>. <source>Cardiovasc Ther</source>. <year>2009</year>;<volume>27</volume>:<fpage>140</fpage>-<lpage>150</lpage>.</citation>
</ref>
<ref id="bibr11-0897190011431635">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Arora</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Loyalka</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kar</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Devices for heart failure: the future is now</article-title>. <source>Congest Heart Fail</source>. <year>2008</year>;<volume>14</volume>:<fpage>141</fpage>-<lpage>148</lpage>.</citation>
</ref>
<ref id="bibr12-0897190011431635">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boilson</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Raichlin</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>SJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Device therapy and cardiac transplantation for end-stage heart failure</article-title>. <source>Curr Probl Cardiol</source>. <year>2010</year>;<volume>35</volume>:<fpage>8</fpage>-<lpage>64</lpage>.</citation>
</ref>
<ref id="bibr13-0897190011431635">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilson</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Givertz</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>GC</given-names>
</name>
<etal/>
</person-group>. <article-title>Ventricular assist devices: the challenges of outpatient management</article-title>. <source>J Am Coll Cardiol</source>. <year>2009</year>;<volume>54</volume>(<issue>18</issue>):<fpage>1647</fpage>-<lpage>1659</lpage>.</citation>
</ref>
<ref id="bibr14-0897190011431635">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kamdar</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Boyle</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of centrifugal, axial, and pulsatile left ventricular assist device support on end-organ function in heart failure patients</article-title>. <source>J Heart Lung Transplant</source>. <year>2009</year>;<volume>28</volume>(<issue>4</issue>):<fpage>352</fpage>-<lpage>359</lpage>.</citation>
</ref>
<ref id="bibr15-0897190011431635">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Radovancevic</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Brtovec</surname>
<given-names>B</given-names>
</name>
<name>
<surname>de Kort</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>End-organ function in patients on long-term circulatory support with continuous-or pulsatile-flow assist devices</article-title>. <source>J Heart Lung Transplant</source>. <year>2007</year>;<volume>26</volume>(<issue>8</issue>):<fpage>815</fpage>-<lpage>818</lpage>.</citation>
</ref>
<ref id="bibr16-0897190011431635">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feller</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Sorensen</surname>
<given-names>EN</given-names>
</name>
<name>
<surname>Haddad</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Clinical outcomes are similar in pulsatile and nonpulsatile left ventricular assist device recipients</article-title>. <source>Ann Thorac Surg</source>. <year>2007</year>;<volume>83</volume>:<fpage>1082</fpage>-<lpage>1088</lpage>.</citation>
</ref>
<ref id="bibr17-0897190011431635">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Birks</surname>
<given-names>EJ</given-names>
</name>
</person-group>. <article-title>Left ventricular assist devices</article-title>. <source>Heart</source>. <year>2010</year>;<volume>96</volume>:<fpage>63</fpage>-<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr18-0897190011431635">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Robertis</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Birks</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Clinical performance with the Levitronix CentriMag short-term ventricular assist device</article-title>. <source>J Heart Lung Transplant</source>. <year>2006</year>;<volume>25</volume>:<fpage>181</fpage>-<lpage>186</lpage>.</citation>
</ref>
<ref id="bibr19-0897190011431635">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilson</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Mudge</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>Stewart</surname>
<given-names>GC</given-names>
</name>
<etal/>
</person-group>. <article-title>Evaluation for a ventricular assist device: selecting the appropriate candidate</article-title>. <source>Circulation</source>. <year>2009</year>;<volume>119</volume>:<fpage>2225</fpage>-<lpage>2232</lpage>.</citation>
</ref>
<ref id="bibr20-0897190011431635">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holman</surname>
<given-names>WL</given-names>
</name>
<name>
<surname>Pae</surname>
<given-names>WE</given-names>
</name>
<name>
<surname>Teutenberg</surname>
<given-names>JJ</given-names>
</name>
<etal/>
</person-group>. <article-title>INTERMACS: interval analysis of registry data</article-title>. <source>J Am Coll Surg</source>. <year>2009</year>;<volume>208</volume>(<issue>5</issue>):<fpage>755</fpage>-<lpage>761</lpage>.</citation>
</ref>
<ref id="bibr21-0897190011431635">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Russo</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>KN</given-names>
</name>
<name>
<surname>Davies</surname>
<given-names>RR</given-names>
</name>
<etal/>
</person-group>. <article-title>Posttransplant survival is not diminished in heart transplant recipients bridged with implantable left ventricular assist devices</article-title>. <source>J Thorac Cardiovasc Surg</source>. <year>2009</year>;<volume>138</volume>(<issue>6</issue>):<fpage>1425</fpage>-<lpage>1432</lpage>.e3.</citation>
</ref>
<ref id="bibr22-0897190011431635">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Osaki</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Edwards</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>MR</given-names>
</name>
<etal/>
</person-group>. <article-title>Improved survival after heart transplantation in patients with bridge to transplant in the recent era: a 17-year single-center experience</article-title>. <source>J Heart Lung Transplant</source>. <year>2009</year>;<volume>28</volume>(<issue>6</issue>):<fpage>591</fpage>-<lpage>597</lpage>.</citation>
</ref>
<ref id="bibr23-0897190011431635">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>DeBakey</surname>
<given-names>ME</given-names>
</name>
</person-group>. <article-title>Left ventricular bypass pump for cardiac assistance: clinical experience</article-title>. <source>Am J Cardiol</source>. <year>1971</year>;<volume>27</volume>(<issue>1</issue>):<fpage>3</fpage>-<lpage>11</lpage>.</citation>
</ref>
<ref id="bibr24-0897190011431635">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farrar</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Holman</surname>
<given-names>WR</given-names>
</name>
<name>
<surname>McBride</surname>
<given-names>LR</given-names>
</name>
<etal/>
</person-group>. <article-title>Long-term follow-up of Thoratec ventricular assist device bridge-to-recovery patients successfully removed from support after recovery of ventricular function</article-title>. <source>J Heart Lung Transplant</source>. <year>2002</year>;<volume>21</volume>:<fpage>516</fpage>-<lpage>521</lpage>.</citation>
</ref>
<ref id="bibr25-0897190011431635">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mountis</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Starling</surname>
<given-names>RC</given-names>
</name>
</person-group>. <article-title>Management of left ventricular assist devices after surgery: bridge, destination, and recovery</article-title>. <source>Curr Opin Cardiol</source>. <year>2009</year>;<volume>24</volume>:<fpage>252</fpage>-<lpage>256</lpage>.</citation>
</ref>
<ref id="bibr26-0897190011431635">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Badiwala</surname>
<given-names>MV</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>V</given-names>
</name>
</person-group>. <article-title>Left ventricular device as destination therapy: are we there yet?</article-title> <source>Curr Opin Cardiol</source>. <year>2009</year>;<volume>24</volume>:<fpage>184</fpage>-<lpage>189</lpage>.</citation>
</ref>
<ref id="bibr27-0897190011431635">
<label>27</label>
<citation citation-type="other">
<collab collab-type="author">Thoratec Corporation press release, January 20, 2010</collab>. <ext-link ext-link-type="uri" xlink:href="www.thoratec.com">www.thoratec.com</ext-link>. <comment>Accessed Oct 5, 2010</comment>.</citation>
</ref>
<ref id="bibr28-0897190011431635">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lietz</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Kfoury</surname>
<given-names>AG</given-names>
</name>
<etal/>
</person-group>. <article-title>Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection</article-title>. <source>Circulation</source>. <year>2007</year>;<volume>116</volume>:<fpage>497</fpage>-<lpage>505</lpage>.</citation>
</ref>
<ref id="bibr29-0897190011431635">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grady</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Mattea</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Improvement in quality of life outcomes 2 weeks after left ventricular assist device implantation</article-title>. <source>J Heart Lung Transplant</source>. <year>2001</year>;<volume>20</volume>:<fpage>657</fpage>-<lpage>669</lpage>.</citation>
</ref>
<ref id="bibr30-0897190011431635">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grady</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Mattea</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Change in quality of life from before to after discharge following left ventricular assist device implantation</article-title>. <source>J Heart Lung Transplant</source>. <year>2003</year>;<volume>22</volume>:<fpage>322</fpage>-<lpage>333</lpage>.</citation>
</ref>
<ref id="bibr31-0897190011431635">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dew</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Kormos</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Winowich</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Quality of life outcomes in left ventricular assist system inpatients and outpatients</article-title>. <source>ASAIO J</source>. <year>1999</year>;<volume>45</volume>:<fpage>218</fpage>-<lpage>225</lpage>.</citation>
</ref>
<ref id="bibr32-0897190011431635">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grady</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Dressler</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Longitudinal change in quality of life and impact on survival after left ventricular assist device implantation</article-title>. <source>Ann Thorac Surg</source>. <year>2004</year>;<volume>77</volume>:<fpage>1321</fpage>-<lpage>1327</lpage>.</citation>
</ref>
<ref id="bibr33-0897190011431635">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Russel</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Milano</surname>
<given-names>CA</given-names>
</name>
<etal/>
</person-group>. <article-title>Renal and hepatic function improve in advanced heart failure patients during continuous-flow support with the HeartMate II left ventricular assist device</article-title>. <source>Circulation</source>. <year>2009</year>;<volume>120</volume>:<fpage>2352</fpage>-<lpage>2357</lpage>.</citation>
</ref>
<ref id="bibr34-0897190011431635">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drakos</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Athanasoulis</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Melliaras</surname>
<given-names>KG</given-names>
</name>
<etal/>
</person-group>. <article-title>Myocardial sympathetic innervation and long-term left ventricular mechanical unloading</article-title>. <source>JACC Cardiovasc Imaging</source>. <year>2010</year>;<volume>3</volume>(<issue>1</issue>):<fpage>71</fpage>-<lpage>75</lpage>.</citation>
</ref>
<ref id="bibr35-0897190011431635">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pagani</surname>
<given-names>FD</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>LW</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>SD</given-names>
</name>
<etal/>
</person-group>. <article-title>Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device</article-title>. <source>J Am Coll Cardiol</source>. <year>2009</year>;<volume>54</volume>(<issue>4</issue>):<fpage>312</fpage>-<lpage>321</lpage>.</citation>
</ref>
<ref id="bibr36-0897190011431635">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sandner</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Zimpfer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zrunke</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Renal function and outcome after continuous flow left ventricular assist device implantation</article-title>. <source>Ann Thorac Surg</source>. <year>2009</year>;<volume>87</volume>(<issue>4</issue>):<fpage>1072</fpage>-<lpage>1078</lpage>.</citation>
</ref>
<ref id="bibr37-0897190011431635">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dandel</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Weng</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Siniawski</surname>
<given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>Prediction of cardiac stability after weaning from left ventricular assist devices in patients with idiopathic dilated cardiomyopathy</article-title>. <source>Circulation</source>. <year>2008</year>;<volume>118</volume>:<fpage>S94</fpage>-<lpage>S105</lpage>.</citation>
</ref>
<ref id="bibr38-0897190011431635">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Genovese</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Dew</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Teuteberg</surname>
<given-names>JJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Early adverse events as predictors of 1-year mortality during mechanical circulatory support</article-title>. <source>J Heart Lung Transplant</source>. <year>2010</year>;<volume>29</volume>:<fpage>981</fpage>-<lpage>988</lpage>.</citation>
</ref>
<ref id="bibr39-0897190011431635">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Starling</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Naka</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Boyle</surname>
<given-names>AJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Results of the post-U.S. Food and Drug administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation</article-title>. <source>J Am Coll Cardiol</source>. <year>2011</year>;<volume>57</volume>(<issue>19</issue>):<fpage>1890</fpage>-<lpage>1898</lpage>.</citation>
</ref>
<ref id="bibr40-0897190011431635">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burgess</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Kilborn</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Keeck</surname>
<given-names>AC</given-names>
</name>
</person-group>. <article-title>Interventions for prevention of post-operative atrial fibrillation and its complications after cardiac surgery: a meta-analysis</article-title>. <source>Eur Heart J</source>. <year>2006</year>;<volume>27</volume>(<issue>23</issue>):<fpage>2846</fpage>-<lpage>2857</lpage>.</citation>
</ref>
<ref id="bibr41-0897190011431635">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ennker</surname>
<given-names>IC</given-names>
</name>
<name>
<surname>Pietrowske</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Vohringer</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Surgical debridement, vacuum therapy, and pectoralis plasty in poststernotomy mediastinitis</article-title>. <source>J Plast Reconstr Aesthet Surg</source>. <year>2009</year>;<volume>62</volume>(<issue>11</issue>):<fpage>1479</fpage>-<lpage>1483</lpage>.</citation>
</ref>
<ref id="bibr42-0897190011431635">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paparella</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Brister</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Buchanan</surname>
<given-names>MR</given-names>
</name>
</person-group>. <article-title>Coagulation disorders of cardiopulmonary bypass: a review</article-title>. <source>Intensive Care Med</source>. <year>2004</year>;<volume>30</volume>(<issue>10</issue>):<fpage>1873</fpage>-<lpage>1881</lpage>.</citation>
</ref>
<ref id="bibr43-0897190011431635">
<label>43</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soderquist</surname>
<given-names>B</given-names>
</name>
</person-group>. <article-title>Surgical site infections in cardiac surgery: microbiology</article-title>. <source>APMIS</source>. <year>2007</year>;<volume>115</volume>(<issue>9</issue>):<fpage>1008</fpage>-<lpage>1011</lpage>.</citation>
</ref>
<ref id="bibr44-0897190011431635">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barnes</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Complications in patients with ventricular assist devices</article-title>. <source>Dimens Crit Care Nurs</source>. <year>2008</year>;<volume>27</volume>(<issue>6</issue>):<fpage>233</fpage>-<lpage>241</lpage>.</citation>
</ref>
<ref id="bibr45-0897190011431635">
<label>45</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Richenbacher</surname>
<given-names>WE</given-names>
</name>
<name>
<surname>Naka</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Raines</surname>
<given-names>EP</given-names>
</name>
<etal/>
</person-group>. <article-title>Surgical management of patients in the REMATCH trial</article-title>. <source>Ann Thorac Surg</source>. <year>2003</year>;<volume>75</volume>(<issue>6 suppl</issue>):<fpage>S86</fpage>-<lpage>S92</lpage>.</citation>
</ref>
<ref id="bibr46-0897190011431635">
<label>46</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zimpfer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wieselthaler</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Czerny</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Neurocognitive function in patients with ventricular assist devices: a comparison of pulsatile and continuous blood flow devices</article-title>. <source>ASAIO J</source>. <year>2006</year>;<volume>52</volume>(<issue>1</issue>):<fpage>24</fpage>-<lpage>27</lpage>.</citation>
</ref>
<ref id="bibr47-0897190011431635">
<label>47</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Genovese</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Dew</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Teuteberg</surname>
<given-names>JJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Incidence and patterns of adverse event onset during the first 60 days after ventricular assist device implantation</article-title>. <source>Ann Thorac Surg</source>. <year>2009</year>;<volume>88</volume>(<issue>4</issue>):<fpage>1162</fpage>-<lpage>1170</lpage>.</citation>
</ref>
<ref id="bibr48-0897190011431635">
<label>48</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bagdasarian</surname>
<given-names>NG</given-names>
</name>
<name>
<surname>Malani</surname>
<given-names>AN</given-names>
</name>
<name>
<surname>Pagani</surname>
<given-names>FD</given-names>
</name>
<etal/>
</person-group>. <article-title>Fungemia associated with left ventricular assist device support</article-title>. <source>J Card Surg</source>. <year>2009</year>;<volume>24</volume>(<issue>6</issue>):<fpage>763</fpage>-<lpage>765</lpage>.</citation>
</ref>
<ref id="bibr49-0897190011431635">
<label>49</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holman</surname>
<given-names>WL</given-names>
</name>
</person-group>. <article-title>Microbiology of infection in mechanical circulatory support</article-title>. <source>Int J Artific Organs</source>. <year>2007</year>;<volume>30</volume>(<issue>9</issue>):<fpage>764</fpage>-<lpage>770</lpage>.</citation>
</ref>
<ref id="bibr50-0897190011431635">
<label>50</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schulman</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Martens</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Russo</surname>
<given-names>MJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Effect of left ventricular assist device infection on post-transplant outcomes</article-title>. <source>J Heart Lung Transplant</source>. <year>2009</year>;<volume>28</volume>(<issue>3</issue>):<fpage>237</fpage>-<lpage>242</lpage>.</citation>
</ref>
<ref id="bibr51-0897190011431635">
<label>51</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Didishem</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Rose</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>JW</given-names>
</name>
<etal/>
</person-group>. <article-title>Infection with clinical ventricular assist devices: clinical therapy</article-title>. <source>ASAIO J</source>. <year>2001</year>;<volume>47</volume>(<issue>3</issue>):<fpage>195</fpage>-<lpage>196</lpage>.</citation>
</ref>
<ref id="bibr52-0897190011431635">
<label>52</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raymond</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Kfoury</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Bishop</surname>
<given-names>CJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Obesity and left ventricular assist device driveline exit site infection</article-title>. <source>ASAIO J</source>. <year>2010</year>;<volume>56</volume>(<issue>1</issue>):<fpage>57</fpage>-<lpage>60</lpage>.</citation>
</ref>
<ref id="bibr53-0897190011431635">
<label>53</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Monkowski</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Axelrod</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Fekete</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Infections associated with ventricular assist devices: epidemiology and effect on prognosis after transplantation</article-title>. <source>Transpl Infect Dis</source>. <year>2007</year>;<volume>9</volume>(<issue>2</issue>):<fpage>114</fpage>-<lpage>120</lpage>.</citation>
</ref>
<ref id="bibr54-0897190011431635">
<label>54</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sivaratnam</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Duggan</surname>
<given-names>JM</given-names>
</name>
</person-group>. <article-title>Left ventricular assist device infections: three case reports and a review of the literature</article-title>. <source>ASAIO J</source>. <year>2002</year>;<volume>48</volume>(<issue>1</issue>):<fpage>2</fpage>-<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr55-0897190011431635">
<label>55</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gordon</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Quagliarello</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lowy</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>Ventricular assist device-related infections</article-title>. <source>Lancet Infect Dis</source>. <year>2006</year>;<volume>6</volume>(<issue>7</issue>):<fpage>426</fpage>-<lpage>437</lpage>.</citation>
</ref>
<ref id="bibr56-0897190011431635">
<label>56</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sinha</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Flannery</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Infections during left ventricular assist device support do not affect post transplant outcomes</article-title>. <source>Circulation</source>. <year>2000</year>;<volume>102</volume>(<issue>19 suppl 3</issue>):<fpage>III194</fpage>-<lpage>III199</lpage>.</citation>
</ref>
<ref id="bibr57-0897190011431635">
<label>57</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chinn</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Dembitsky</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Eaton</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Multicenter experience: prevention and management of left ventricular assist device infections</article-title>. <source>ASAIO J</source>. <year>2005</year>;<volume>51</volume>(<issue>4</issue>):<fpage>461</fpage>-<lpage>470</lpage>.</citation>
</ref>
<ref id="bibr58-0897190011431635">
<label>58</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Argenziano</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Catanese</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Moazami</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>The influence of infection on survival and successful transplantation in patients with left ventricular assist devices</article-title>. <source>J Heart Lung Transplant</source>. <year>1997</year>;<volume>16</volume>(<issue>8</issue>):<fpage>822</fpage>-<lpage>831</lpage>.</citation>
</ref>
<ref id="bibr59-0897190011431635">
<label>59</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malehsa</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Bara</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Acquired von Willebrand syndrome after exchange of the HeartMate XVE to the HeartMate II ventricular assist device</article-title>. <source>Eur J Cardiothorac Surg</source>. <year>2009</year>;<volume>35</volume>(<issue>6</issue>):<fpage>1091</fpage>-<lpage>1093</lpage>.</citation>
</ref>
<ref id="bibr60-0897190011431635">
<label>60</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steinlechner</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Dworschak</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Birkenberg</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Platelet dysfunction in outpatients with left ventricular assist devices</article-title>. <source>Ann Thorac Surg</source>. <year>2009</year>;<volume>87</volume>(<issue>1</issue>):<fpage>131</fpage>-<lpage>137</lpage>.</citation>
</ref>
<ref id="bibr61-0897190011431635">
<label>61</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meyer</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Melehsa</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bara</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Acquired von Willebrand syndrome in patients with an axial flow left ventricular assist device</article-title>. <source>Circ Heart Fail</source>. <year>2010</year>;<volume>3</volume>(<issue>6</issue>):<fpage>685</fpage>-<lpage>681</lpage>.</citation>
</ref>
<ref id="bibr62-0897190011431635">
<label>62</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crow</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Milano</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients</article-title>. <source>Ann Thorac Surg</source>. <year>2010</year>;<volume>90</volume>(<issue>4</issue>):<fpage>1263</fpage>-<lpage>1269</lpage>.</citation>
</ref>
<ref id="bibr63-0897190011431635">
<label>63</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Slaughter</surname>
<given-names>MS</given-names>
</name>
</person-group>. <article-title>Hematologic effects of continuous flow left ventricular assist devices</article-title>. <source>J Cardiovasc Transl Res</source>. <year>2010</year>;<volume>3</volume>(<issue>6</issue>):<fpage>618</fpage>-<lpage>624</lpage>.</citation>
</ref>
<ref id="bibr64-0897190011431635">
<label>64</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uriel</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Pak</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Jorde</surname>
<given-names>UP</given-names>
</name>
<etal/>
</person-group>. <article-title>Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation</article-title>. <source>J Am Coll Cardiol</source>. <year>2010</year>;<volume>56</volume>(<issue>15</issue>):<fpage>1207</fpage>-<lpage>13</lpage>. </citation>
</ref>
<ref id="bibr65-0897190011431635">
<label>65</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lazar</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Shapiro</surname>
<given-names>PA</given-names>
</name>
<name>
<surname>Jaski</surname>
<given-names>BE</given-names>
</name>
<etal/>
</person-group>. <article-title>Neurological events during long-term mechanical circulatory support for heart failure: the Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH)) experience</article-title>. <source>Circulation</source>. <year>2004</year>;<volume>109</volume>(<issue>20</issue>):<fpage>2423</fpage>-<lpage>2427</lpage>.</citation>
</ref>
<ref id="bibr66-0897190011431635">
<label>66</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petrucci</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Truesdell</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Cognitive dysfunction in advanced heart failure and prospective cardiac assist device patients</article-title>. <source>Ann Thorac Surg</source>. <year>2006</year>;<volume>81</volume>(<issue>5</issue>):<fpage>1738</fpage>-<lpage>1744</lpage>.</citation>
</ref>
<ref id="bibr67-0897190011431635">
<label>67</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tsukui</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Abla</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Teuteber</surname>
<given-names>JJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Cerebrovascular accidents in patients with a ventricular assist device</article-title>. <source>J Thorac Cardiovasc Surg</source>. <year>2007</year>;<volume>134</volume>:<fpage>114</fpage>-<lpage>123</lpage>.</citation>
</ref>
<ref id="bibr68-0897190011431635">
<label>68</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Slaughter</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Sobieski</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Gallagher</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Dia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Silver</surname>
<given-names>MA</given-names>
</name>
</person-group>. <article-title>Low incidence of neurologic events during long-term support with the HeartMate XVE left ventricular assist device</article-title>. <source>Tex Heart Inst J</source>. <year>2008</year>;<volume>35</volume>:<fpage>245</fpage>-<lpage>249</lpage>.</citation>
</ref>
<ref id="bibr69-0897190011431635">
<label>69</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Atiemo</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Conte</surname>
<given-names>JV</given-names>
</name>
<name>
<surname>Heldman</surname>
<given-names>AW</given-names>
</name>
</person-group>. <article-title>Resuscitation and recovery from acute right ventricular failure using a percutaneous right ventricular assist device</article-title>. <source>Catheter Cardiovasc Interv</source>. <year>2006</year>;<volume>68</volume>(<issue>1</issue>):<fpage>78</fpage>-<lpage>82</lpage>.</citation>
</ref>
<ref id="bibr70-0897190011431635">
<label>70</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dang</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Topkara</surname>
<given-names>VK</given-names>
</name>
<name>
<surname>Mercando</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Right heart failure after left ventricular assist device implantation in patients with chronic congestive heart failure</article-title>. <source>J Heart Lung Transplant</source>. <year>2006</year>;<volume>25</volume>(<issue>1</issue>):<fpage>1</fpage>-<lpage>6</lpage>.</citation>
</ref>
<ref id="bibr71-0897190011431635">
<label>71</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kavarana</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Pessin-Minsley</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Urtecho</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Right ventricular dysfunction and organ failure in left ventricular assist device recipients: a continuing problem</article-title>. <source>Ann Thorac Surg</source>. <year>2002</year>;<volume>73</volume>:<fpage>745</fpage>-<lpage>750</lpage>.</citation>
</ref>
<ref id="bibr72-0897190011431635">
<label>72</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>De Santo</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Mastroianni</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Romano</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Role of sildenafil in acute posttransplant right ventricular dysfunction: successful experience in 13 consecutive patients</article-title>. <source>Transplant Proc</source>. <year>2008</year>;<volume>40</volume>(<issue>6</issue>):<fpage>2015</fpage>-<lpage>2018</lpage>.</citation>
</ref>
<ref id="bibr73-0897190011431635">
<label>73</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Butler</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Geisberg</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Howser</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Relationship between renal function and left ventricular assist device use</article-title>. <source>Ann Thorac Surg</source>. <year>2006</year>;<volume>81</volume>:<fpage>1745</fpage>-<lpage>1751</lpage>.</citation>
</ref>
<ref id="bibr74-0897190011431635">
<label>74</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alba</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ivanov</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Predictors of acute renal dysfunction after ventricular assist device placement</article-title>. <source>J Card Fail</source>. <year>2009</year>;<volume>15</volume>(<issue>10</issue>):<fpage>874</fpage>-<lpage>881</lpage>.</citation>
</ref>
<ref id="bibr75-0897190011431635">
<label>75</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Masai</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sawa</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ohtake</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Hepatic dysfunction after left ventricular mechanical assist in patients with end-stage heart failure: role of inflammatory response and hepatic microcirculation</article-title>. <source>Ann Thorac Surg</source>. <year>2002</year>;<volume>73</volume>:<fpage>549</fpage>-<lpage>555</lpage>.</citation>
</ref>
<ref id="bibr76-0897190011431635">
<label>76</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amir</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Kar</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Kar</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Recovery from multi-organ failure in a patient with a continuous-flow left ventricular assist device</article-title>. <source>J Heart Lung Transplant</source>. <year>2005</year>;<volume>24</volume>(<issue>8</issue>):<fpage>1128</fpage>-<lpage>1129</lpage>.</citation>
</ref>
<ref id="bibr77-0897190011431635">
<label>77</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Topkara</surname>
<given-names>VK</given-names>
</name>
<name>
<surname>Dang</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Barili</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Predictors and outcomes of continuous veno-venous hemodialysis use after implantation of a left ventricular assist device</article-title>. <source>J Heart Lung Transplant</source>. <year>2006</year>;<volume>25</volume>(<issue>4</issue>):<fpage>404</fpage>-<lpage>408</lpage>.</citation>
</ref>
<ref id="bibr78-0897190011431635">
<label>78</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bedi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kormos</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Winowich</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Ventricular arrhythmias during left ventricular assist device support</article-title>. <source>Am J Cardiol</source>. <year>2007</year>;<volume>99</volume>:<fpage>1151</fpage>-<lpage>1153</lpage>.</citation>
</ref>
<ref id="bibr79-0897190011431635">
<label>79</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ziv</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Dizon</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Thosani</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Effects of left ventricular assist device therapy on ventricular arrhythmias</article-title>. <source>J Am Coll Cardiol</source>. <year>2005</year>;<volume>45</volume>(<issue>9</issue>):<fpage>1428</fpage>-<lpage>1434</lpage>.</citation>
</ref>
<ref id="bibr80-0897190011431635">
<label>80</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Osaki</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Alberte</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>MA</given-names>
</name>
<etal/>
</person-group>. <article-title>Successful radiofrequency ablation therapy for intractable ventricular tachycardia with a ventricular assist device</article-title>. <source>J Heart Lung Transplant</source>. <year>2008</year>;<volume>27</volume>(<issue>3</issue>):<fpage>353</fpage>-<lpage>356</lpage>.</citation>
</ref>
<ref id="bibr81-0897190011431635">
<label>81</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Birks</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Tansley</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Yacoub</surname>
<given-names>MH</given-names>
</name>
<etal/>
</person-group>. <article-title>Incidence and clinical management of life-threatening left ventricular assist device failure</article-title>. <source>J Heart Lung Transplant</source>. <year>2004</year>;<volume>23</volume>(<issue>8</issue>):<fpage>964</fpage>-<lpage>969</lpage>.</citation>
</ref>
<ref id="bibr82-0897190011431635">
<label>82</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adamson</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Dembitsky</surname>
<given-names>WP</given-names>
</name>
<name>
<surname>Bardarin</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Heartmate left ventricular assist system exchange: results and technical considerations</article-title>. <source>ASAIO J</source>. <year>2009</year>;<volume>55</volume>:<fpage>598</fpage>-<lpage>601</lpage>.</citation>
</ref>
<ref id="bibr83-0897190011431635">
<label>83</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dudzinski</surname>
<given-names>DM</given-names>
</name>
</person-group>. <article-title>Ethics guidelines for destination therapy</article-title>. <source>Ann Thorac Surg</source>. <year>2006</year>;<volume>81</volume>(<issue>4</issue>):<fpage>1185</fpage>-<lpage>1188</lpage>.</citation>
</ref>
<ref id="bibr84-0897190011431635">
<label>84</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rizzieri</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Verheijde</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Rady</surname>
<given-names>MY</given-names>
</name>
<etal/>
</person-group>. <article-title>Ethical challenges with the left ventricular assist device as a destination therapy</article-title>. <source>Philos Ethics Humanit Med</source>. <year>2008</year>;<volume>3</volume>:<fpage>20</fpage>.</citation>
</ref>
<ref id="bibr85-0897190011431635">
<label>85</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schaffer</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Weiss</surname>
<given-names>ES</given-names>
</name>
<etal/>
</person-group>. <article-title>Infectious complications after pulsatile-flow and continuous-flow left ventricular assist device implantation</article-title>. <source>J Heart Lung Transplant</source>. <year>2011</year>;<volume>30</volume>(<issue>2</issue>):<fpage>164</fpage>-<lpage>174</lpage>.</citation>
</ref>
<ref id="bibr86-0897190011431635">
<label>86</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herrmann</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Weyland</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Greshake</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Left ventricular assist device infection is associated with increased mortality but is not a contraindication to transplantation</article-title>. <source>Circulation</source>. <year>1997</year>;<volume>95</volume>(<issue>4</issue>):<fpage>814</fpage>-<lpage>817</lpage>.</citation>
</ref>
<ref id="bibr87-0897190011431635">
<label>87</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holman</surname>
<given-names>WL</given-names>
</name>
<name>
<surname>Rayburn</surname>
<given-names>BK</given-names>
</name>
<name>
<surname>McGiffen</surname>
<given-names>DC</given-names>
</name>
<etal/>
</person-group>. <article-title>Infection in ventricular assist devices: prevention and treatment</article-title>. <source>Ann Thorac Surg</source>. <year>2003</year>;<volume>75</volume>(<issue>6 suppl</issue>):<fpage>S48</fpage>-<lpage>S57</lpage>.</citation>
</ref>
<ref id="bibr88-0897190011431635">
<label>88</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fries</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Innerhofer</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Streif</surname>
<given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Coagulation monitoring and management of anticoagulation during cardiac assist device support</article-title>. <source>Ann Thorac Surg</source>. <year>2003</year>;<volume>76</volume>(<issue>5</issue>):<fpage>1593</fpage>-<lpage>1597</lpage>.</citation>
</ref>
<ref id="bibr89-0897190011431635">
<label>89</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boyle</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Teuteberg</surname>
<given-names>JJ</given-names>
</name>
<etal/>
</person-group>. <article-title>Low thromboembolism and pump thrombosis with the Heartmate II left ventricular assist device: analysis of outpatient anti-coagulation</article-title>. <source>J Heart Lung Transplant</source>. <year>2009</year>;<volume>28</volume>(<issue>9</issue>):<fpage>881</fpage>-<lpage>887</lpage>.</citation>
</ref>
<ref id="bibr90-0897190011431635">
<label>90</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>John</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kamdar</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Low thromboembolic risk for patients with the Heartmate II left ventricular assist device</article-title>. <source>J Thorac Cardiovasc Surg</source>. <year>2008</year>;<volume>136</volume>(<issue>5</issue>):<fpage>1318</fpage>-<lpage>1323</lpage>.</citation>
</ref>
<ref id="bibr91-0897190011431635">
<label>91</label>
<citation citation-type="book">
<source>Heartmate XVE LVAS: Clinical Operation &amp; Patient Management</source>. <publisher-loc>Pleasanton, CA</publisher-loc>: <publisher-name>Thoratec Corporation</publisher-name>; <year>2006</year>.</citation>
</ref>
<ref id="bibr92-0897190011431635">
<label>92</label>
<citation citation-type="book">
<source>Heartmate II LVAS: Clinical Operation &amp; Patient Management</source>. <publisher-loc>Pleasanton, CA</publisher-loc>: <publisher-name>Thoratec Corporation</publisher-name>; <year>2008</year>.</citation>
</ref>
<ref id="bibr93-0897190011431635">
<label>93</label>
<citation citation-type="book">
<source>Thoratec Laboratories: Clinical Operation &amp; Patient Management</source>. <publisher-loc>Pleasanton, CA</publisher-loc>: <publisher-name>Thoratec Corporation</publisher-name>; <year>2006</year>.</citation>
</ref>
<ref id="bibr94-0897190011431635">
<label>94</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dickstein</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Cohen-Solal</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Filippatos</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the taskforce for the diagnosis and treatment of acute and chronic heart failure 2008 European society of cardiology</article-title>. <source>Eur Heart J</source>. <year>2008</year>;<volume>29</volume>(<issue>19</issue>):<fpage>2388</fpage>-<lpage>2442</lpage>.</citation>
</ref>
<ref id="bibr95-0897190011431635">
<label>95</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pitt</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zannad</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Remme</surname>
<given-names>WJ</given-names>
</name>
<etal/>
</person-group>. <article-title>The effect of spironolactone on morbidity and mortality in patients with severe heart failure</article-title>. <source>N Engl J Med</source>. <year>1999</year>;<volume>341</volume>(<issue>10</issue>):<fpage>709</fpage>-<lpage>717</lpage>.</citation>
</ref>
<ref id="bibr96-0897190011431635">
<label> 96</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schmid</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wilhelm</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rothenburger</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Effect of high dose platelet inhibitor treatment on thromboembolism in Novacor patients</article-title>. <source>Eur J Cardiothorac Surg</source>. <year>2000</year>;<volume>17</volume>:<fpage>331</fpage>-<lpage>335</lpage>.</citation>
</ref>
<ref id="bibr97-0897190011431635">
<label> 97</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sandner</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Zimpfer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zrunek</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group>. <article-title>Low molecular weight heparin as an alternative to unfractionated heparin in the immediate postoperative period after left ventricular assist device implantation</article-title>. <source>Artific Organs</source>. <year>2008</year>;<volume>32</volume>(<issue>10</issue>):<fpage>819</fpage>-<lpage>822</lpage>.</citation>
</ref>
<ref id="bibr98-0897190011431635">
<label> 98</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meuris</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Arnout</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Vlasselaers</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>Long-term management of an implantable left ventricular assist device using low molecular weight heparin and antiplatelet therapy: a possible alternative to oral anticoagulants</article-title>. <source>Artific Organs</source>. <year>2007</year>;<volume>31</volume>(<issue>5</issue>):<fpage>402</fpage>-<lpage>419</lpage>.</citation>
</ref>
<ref id="bibr99-0897190011431635">
<label> 99</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ades</surname>
<given-names>PA</given-names>
</name>
</person-group>. <article-title>Cardiac rehabilitation and secondary prevention of coronary heart disease</article-title>. <source>N Engl J Med</source>. <year>2001</year>;<volume>345</volume>(<issue>12</issue>):<fpage>892</fpage>-<lpage>902</lpage>.</citation>
</ref>
<ref id="bibr100-0897190011431635">
<label>100</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dent</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Noonan</surname>
<given-names>CW</given-names>
</name>
</person-group>. <article-title>Tobacco interventions delivered by pharmacists: a summary and systematic review</article-title>. <source>Pharmacotherapy</source>. <year>2007</year>;<volume>27</volume>(<issue>7</issue>):<fpage>1040</fpage>-<lpage>1051</lpage>.</citation>
</ref>
<ref id="bibr101-0897190011431635">
<label>101</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sokos</surname>
<given-names>DR</given-names>
</name>
</person-group>. <article-title>Pharmacists' role in increasing pneumococcal and influenza vaccination</article-title>. <source>Am J Health Syst Pharm</source>. <year>2005</year>;<volume>62</volume>(<issue>4</issue>):<fpage>367</fpage>-<lpage>377</lpage>.</citation>
</ref>
<ref id="bibr102-0897190011431635">
<label>102</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malone</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Alger-Mayer</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>DA</given-names>
</name>
</person-group>. <article-title>The lifestyle challenge program: a multidisciplinary approach to weight management</article-title>. <source>Ann Pharmacother</source>. <year>2005</year>;<volume>39</volume>(<issue>12</issue>):<fpage>2015</fpage>-<lpage>2020</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>